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ABSTRACT

An initial investigation reporting the excellent suitability of an
MSV-induced osteosarcoma in rats as a model of the human disease has been
confirmed and extended. Intratibial inoculation of the virus in newborn
animals has reproducibly caused a localized, osteoid-producing tumor mass
which is rapidly progressive and fatal (median survival = 20.0 days). The
histologic nature, incidence, and distribution of metastatic disease in
this tumor model are comparable in most respects to osteosarcoma in man.
Particularly significant was the 89% incidence of metastatic pulmonary di¬
sease in tumor-bearing groups from 10 to 65 days of age.
Tumor-specific cellular and humoral responses were demonstrated in
animal groups tested between 14 and 48 days of age. Use of an in vitro
cytotoxicity assay demonstrated a biphasic pattern to both cellular and hu¬
moral cytotoxicity, and the theoretical correlates and implications of
these kinetics have been discussed. Humoral factors consistently increased
the levels of cell-mediated immunity in untreated tumor-bearing animals.
The efficacy of adriamycin chemotherapy in human osteosarcoma stim¬
ulated its use in the rat model, where its effects were twofold. The net
effect of adriamycin treatment at two doses and a single schedule was bene¬
ficial due to its tumoricidal actions. Treated animals exhibited signifi¬
cantly retarded tumor growth and survived significantly longer than un¬
treated tumor-bearing controls. Importantly, adriamycin treatment was not
associated with suppression of tumor-specific cell-mediated immunity. In
addition, however, use of adriamycin was associated with a possibly doserelated in vivo and in vitro enhancement phenomenon, as treated animals dev¬
eloped significantly more long bone metastases than controls, and exhi¬
bited blocking activity in their sera. It has been postulated that this
enhancement was caused by adriamycin-induced antigenic shedding by the tu¬
mor, with the consequent formation of serum blocking factors.
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Introduction

A.

The Relationship between Immunity and Malignancy

The Concept of Immune Surveillance:
In a lecture on cancer given in 1908, the brilliant German founder
of immunology, Paul Ehrlich, first proposed that there exists a funda¬
mental relationship between immunity and malignancy.

In this lecture

he stated:
"The understanding of natural immunity represents the
key to carcinoma... I am certain that, in the enor¬
mously complicated course of fetal and post-fetal
development, aberrant cells become unusually common.
Fortunately, in the majority of people, they remain
completely latent thanks to the organism's positive
mechanisms. If such mechanisms did not exist, one
might expect carcinomas to have an enormous frequency.
These cells may live in a latent state for 20, 30 or
40 years before changing to a significant tumor.
This means, in light of my theory, that there has
been a diminution of some vital cell activity
[which] allows the rapid, parasitic growth of cer¬
tain cells. "90
Ehrlich's amazing insight was apparently not fully appreciated,
however, as only one report (in 1924)

until the last two decades

mentioned the potential significance of host immunity as a defense
against neoplasia.

Renewed interest in immunological studies of cancer

followed the landmark experiments by Foley (1953)
(1957)^, and Klein (1966)^.

112

, Prehn and Main

These studies established the presence

of tumor-associated antigens, and together with observations of cancer
epidemiology, laid the foundations for a most powerful influence on
cancer research -- the theory of inmunologi cal surveillance.

2-

-

A1 though clearly suggested by Ehrlich in 1908, the theory in its
modern form was formulated by Lewis Thomas in a discussion of transplantation inmunity in 1959.

316

On considering the "underlying meaning

of homograft rejection, as a biological phenomenon", Thomas proposed
that "homograft rejection will turn out to represent a primary mecha¬
nism for natural defense against neoplasia".
Burnet in 1963

42

Stimulated by this concept,

first used the term "surveillance" to characterize

this relationship.
Stated more precisely, the thesis of immune surveillance theory is
that when aberrant cells with prol iferative potential arise in the body,
they carry new antigenic determinants on their cell surface.

When a

sufficient amount of new antigen is present, a cellular, mainly thymusdependent immunological response is initiated which eventually elimi¬
nates the aberrant cells in essentially the same way that a homograft
is destroyed.

43

While of great clinical and heuristic importance, this theory has
at its foundation a sound evolutionary explanation.

Though some have

casually proposed that the raison d'etre of the irnnune system lies in
its elimination of neoplastic cells. Good and Finstad

131 132
’
have

studied in depth the evolution of the immune response, and draw some
very intriguing conclusions.

In brief, they have proposed that the

vertebrate capacities for malignancy and immune competence developed
concomitantly in phylogeny.

Both, they suggest, evolved as a function

of a more basic impulse to cellular variation in higher, vertebrate
forms.

While the capacity for somatic mutation per se could have been

of major survival advantage, "malignant adaptation" may have either

3-

-

been an undesirable side effect, or teleologically, have had its own
survival value in protecting ecological niches from exhaustion by groups
of each vertebrate form.

The immunological adaptation, in turn, pro¬

gressively developed a capacity for surveillance against the threat of
malignant adaptation.

From this view, as stated by Burnet in his 1960

Nobel prize speech, "the faculty of immunological recognition becomes
an intrinsic part of the homeostatic controls that maintain the body
as a going concern".

41

Cited as evidence for this evolutionary theory is the inability of
investigators to identify malignancies in invertebrate forms; the
failure of vertebrate carcinogens to induce malignancies
doses of irradiation to kill, these lower forms, and

in, or high

the congruous

inability of investigators to define invertebrate immune cells or reac¬
tions.

On the other hand, both cellular immunity and definite malig¬

nancies have consistently been described in all vertebrate forms,
including fishes, amphibians, reptiles, birds and mammals.

Clinical Evidence for Immunologic Surveillance:
Burnet

43

suggested that there are at least four predictions made

by the theory of immunologic surveillance at the clinical level:
1.

There should be an increased incidence of malignancy initiated
at ages of relative immunologic incompetence.

2.

Pathologic conditions associated with deficiencies of thymusdependent immunity should be associated with a higher incidence
of neoplasia.

4-

-

3.

Spontaneous remissions of clinically evident malignancy should
occur.

4.

Unselected autopsies or pathologic specimens should show larger
numbers of malignant foci than could ever develop to definite
tumors.

A few recent reports have elegantly reviewed the wealth of clini¬
cal evidence supporting these predictions; however, several points are
noteworthy for this discussion.
First, cancer is largely a disease of the very old and the very
young.

The age incidence of many childhood tumors is compatible with

a process initiated about the time of birth
immunoincompetence.

257

, a time of relative

At the other extreme, consistent with thymic invo-

lution and a decrease in immunologic vigor with advanced age
malignant cells flourish.

While humoral and re-call immunity (to pre-

viously experienced antigen) are adequate in the elderly
1 qo

QC"7

0“7 c

12 314
’
,

12 41 43 131
* * *
’

Q1/1
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^ responses to new and thymic-dependent antigens are

markedly depressed.

More than 95% of individuals under age 65 can be

sensitized to dinitrochlorobenzene, whereas only 20-30% of patients
over 65 can be so sensitized.

91

In addition, old people with malig-

nancies do less well with these identical

1 89

or similar

1 88

immunologic

procedures than do other noncancerous patients with chronic disease,
or normal individuals of the same age.
Convincing evidence for the second prediction -- that pathologic
conditions associated with diminished thymus-dependent immunity have an
increased incidence of malignancy -- comes from two sources.

The first

5-

-

area includes what Good calls "experiments of nature"

1 31

, in which

immunological deficiency diseases are associated with a significantly
higher incidence of malignancy.

Particularly striking are the Wiskott-

Aldrich and ataxia-telangiectasia syndromes, conditions of defective
ontogenetic thymus-dependent lymphoid development.

In these conditions,

malignancy has been the cause of death in fully 13 and 10% of reported
cases, respectively.

21 2

When all acquired and congenital immunodefi¬

ciency disorders are considered together, a very conservative estimate
of the incidence of malignancy is about 5%, or about 200 times the
expected rate.^
The second area involves malignancy associated with long-term
iatrogenic immunosuppression in organ (mainly renal) transplant recipi¬
ents.

Immunosuppression for transplantation generally consists of

azathi oprine, prednisone, anti lymphocyte serum and/or a variety of
other methods generally intended to diminish thymus-dependent immunity.
The incidence of de novo malignancies here is approximately 5.6% in
patients averaging 38 years of age, or approximately 100 times the expected rate.

250

A remarkable fact reported by Penn

250

is that a wide

variety of histological malignancies have been encountered.

The most

common lesions were cancers of the skin and lips (39%), followed by
solid lymphomas (27%), carcinomas of the cervix and uterus (8%), lung
(5%), and miscellaneous (21%).
by Woodruff

334

Perhaps even more notable is the report

that withdrawal of immunosuppressive regimens has caused

regressions of tumors arising in transplant recipients.

Some would hold

that these data do not necessarily support immunological surveillance,
but rather represent diminished host defenses against oncogenic viruses

6-

-

qua infectious agents.

203

Nevertheless, the variety of malignancies

observed (including, for example, lung cancer), and the occurrence of
"spontaneous" tumor regressions upon withdrawal of immunosuppressives
both support a role for host tumor-specific defense mechanisms.
"Spontaneous" tumor regressions have been well documented in other,
non-transplant patients as well.
cal by Everson

98

Of 130 instances considered unequivo-

, more than half fall into one of four categories:

neuroblastoma of adrenal and related tissues, 28; hypernephroma, 21;
choriocarcinoma, 13; and malignant melanoma, 12.

It is pertinent that

all these tumors arise either in children or in adults younger than
those susceptible to the common malignant diseases.

43

Finally, consistent with Burnet's fourth prediction, at least
four types of malignant tumors (neuroblastoma
and cervical

10

, thyroid

222

, prostatic

227

carcinomas) are much more frequently diagnosed in random

pathological specimens than they are found clinically in comparable
populations.

An unavoidable interpretation is that many accumulations

of malignant cells never progress to overt malignancy, but instead are
"kept in check"

or destroyed by host defense mechanisms.

Supporting

this interpretation is the finding that the intensity of the host cel¬
lular response in specimens of a wide variety of malignancies is directly
correlated with prognosis.26,70,123,193

Experimental Evidence:
A wealth of experimental evidence also exists to support the involve
ment of host defenses, especially thymus-derived lymphocytes (abbreviated
"T-cells"), in surveillance and destruction of neoplastic cells.

Perhaps

7-

-

the best evidence is that derived from studies of tumors induced by both
DNA and RNA oncogenic viruses in which ablation of thymus-dependent
functions has been associated with a high incidence of malignancy.
Thymectomy or anti-lymphocyte serum (ALS) treatment permits the appear¬
ance of tumors in mice and rats deliberately or naturally infected with
the DNA polyoma virus- ^^323,324

purtherm0re, reconstitution with

tumor-sensitized thymus, spleen or lymph node cells in these immuno¬
logic cripples prevents the development of the malignancies."'^84,29^1
Likewise, susceptibility of mice and rats to oncogenesis by a variety
of C-type RNA viruses is significantly increased by many immunosuppressive
procedures, including thymectomy00’
ment with ALS

*

, cortisone

, irradiationJU , and treat, cytoxan

or daunomycin.

While some apparently contradictory evidence exists with thymectomy in
TOO

mouse leukemia vi rus-induced tumors
microenvironment for tumor progression

IOO

’
1 8?

pifi

5

, which require the thymic

, overwhelming evidence exists

to support immune surveillance in experimental virus-induced tumors.
The interactions of virus, immunity, and malignancy are made some¬
what more complex by the fact that most oncogenic viruses are in them¬
selves immunosuppressive.^

Thus, oncogenic viruses may: (1) induce

neoplasia per se, which can then be facilitated by other forms of immuno¬
suppression; or (2) cause immunosuppression primarily, making the host
more susceptible to the neoplastic process.

251

In this context, it is

interesting that the onset of malignancies induced by Friend leukemia
virus (FLV) in mice are always preceded by the immunosuppressive effects
of FLV.

71

8-

-

Carcinogenic hydrocarbons also suppress host immunity, both humoral

299 301
1 80 25P
*
and cellular
*
, while noncarcinogeni c hydrocarbons

do not.

299

The evidence for the effects of additional immunosuppression

on chemical carcinogenesis is somewhat conflicting

; however, thy¬

mectomy and/or ALS treatment have usually resulted in an increased
incidence of tumors, a decreased latency, or both, when animals are
o/r

given chemical carcinogens.

ooc

~7

’

Other experimental approaches supporting the significance of host
immunity in defense against malignancy have included: (1) the increased
incidence of spontaneous tumors in deliberately immunosuppressed animals;
and (2) the documented immunoincompetence of animals, such as AKR and
NZB mice, which have a naturally high incidence of malignancy.

85 205
’

The Demonstration of Tumor-Specific Transplantation Antigens (TSTA):
Pivotal to this entire discussion of immunological surveillance
is the concept that tumors are antigenic.

As early as the turn of the

century the hope was held that dissimilarities between neoplastic and
normal cells would enable the development of an anti-cancer vaccine,
and transplantation experiments seemed to show the presence of tumorspecific antigens.

The field of tumor immunology later fell into

disrepute when it was recognized that these claims of tumor-speci fi ci ty
were based on experiments in which immunity to normal alloantigens,
rather than tumor-specific antigens, had been evoked.

331

The demonstration of TSTA awaited the development of highly inbred
strains of mice which approached homozygosity so closely that individual
animals could retain skin grafts from others of the same strain (syngeneic

9-

-

animals).

Only in syngeneic systems is it possible to analyze the con¬

ditions that cause retention or rejection of either normal or neoplastic
tissues, since in any allogeneic or xenogeneic combination, tumor spe¬
cificities may be masked by strain-speci fi c or species-specific antigens.
It was under these conditions that Foley (in 1953)
Prehn and Main

261

112

, and later

, first demonstrated TSTA in methylcholanthrene (MCA)-

induced tumors of mice.

Their experiments showed that otherwise pro¬

gressive syngeneic MCA-induced tumors failed to grow if mice challenged
with tumor cells had been pre-treated with the same tumor cells.

Immu¬

nization with normal tissue, or other MCA tumors, was not protective.
By preimmunization, then, these investigators showed that there were
antigens unique to the tumor.
Subsequently it has been widely confirmed that specific antigeni¬
city accompanies neoplastic transformation of most cells, whether this
transformation is spontaneous
170 237 294
or oncogenic virus. *■
’
methods

289

328

, or effected by a chemical carcinogen

251

In addition to in vivo transplantation

, in vitro methods demonstrating TSTA have included membrane

immunofluorescence'^, colony inhibition tests'^, and various forms of
cellular and humoral cytotoxicity assays.

37 309
’

These methods have con¬

vincingly demonstrated the presence of tumor-specific antigens in a
wide variety of animal tumor systems as well as several malignancies in
man.
As a rule, TSTA of virus-induced tumors is the same for all tumors
induced by the same virus, regardless of histologic type or animal
species, but differs in tumors induced by different viruses.
This is true for both DNA and RNA viruses.

170 237 294
’
’

Recent evidence suggests

,

10-

-

that polyoma virus tumors have individually unique antigens in addition
to their common antigens, however.

The tumor-specific antigens

associated with a given virus do not represent virus particles gathered
at the cell surface, but rather seem to be components of the tumor cell
distinct from intact virions.
Conversely, and implicit in the MCA tumor studies above, chemically
induced neoplasms produce tumor-specific antigens which do not cross
react.

170 237 294
’
’

Thus, in the example cited, preimmunization with

tumor cells of a different MCA-induced neoplasm did not protect against
the malignant potential of the original MCA tumor challenge.
to this rule have been reported

234

Exceptions

, but in general, TSTA's associated

with carcinogens are unique for each tumor produced.
The demonstration of antigenic cross-reactivity between a tumor of
unknown etiology and a second tumor of known viral causation justifies
the search for a causative virus in the first tumor, but does not prove
that they are induced by the same virus.

First, a phenomenon known as

"antigenic conversion" may have occurred, whereby a common tumor antigen
has been secondarily acquired (e.g., through viral superinfection) by
the neoplastic cells.

Second, activation of genes normally only

expressed in embryonic states may have occurred, producing "cardnofetal
antigens.

Three such antigens identified in man are: (1) "carcinoembry-

onic" antigen (CEA), associated primarily, but not exclusively, with
adenocarcinomas of the digestive tract

; (2) a-fetoprotein, an antigen

produced by hepatoma cells and some testicular neoplasms'^; and (3) yfetoprotein, a fetal antigen produced by a wide variety of primarily
malignant tumors.

89

Finally, genes that are normally redundant may have

11-

-

been activated in the transformed cells, as is the case with the TL
antigens of mouse leukemias.

32

Mechanisms of "Escape" from Immunologic Surveillance:
A common view in the past has been that tumor-specific antigens
could not possibly exist, since they would result in the immediate im¬
munologic recognition and destruction of the cells which carried them.
The existence of tumors in apparently "normal" individuals, in addition
to the presence of common lymph node metastases, was taken as prima facie
evidence for nonantigenicity.

Yet, as discussed above, TSTA has been

clearly demonstrated in almost every tumor system in which its presence
has been evaluated.

Why, then, do some tumors not get rejected?

At the outset, it is important to state that tumor progression or
rejection is an extremely complex phenomenon which probably has no single
explanation.
plasia

It is perhaps useful to consider host immunity and neo¬

as independent components of resulting clinical disease, although

it will be made clear that this is a somewhat artificial distinction.
In some instances, presumably independent genetic factors cause
thymus-dependent immunity to be markedly diminished or absent, allowing
neoplastic cells to proliferate unchecked.

Good's "experiments of

nature", and malignancies of the very old and the very young, fit most
easily into this category.
It has already been suggested that the immunosuppressive nature of
both viral and chemical oncogens may allow antigenic tumors to develop,
over and above their abilities to transform cells.

12-

-

Growing tumors, in themselves, may be non-speci fi cal ly immuno¬
suppressive, perhaps through elaboration of "factors" that depress
immunologic reactivity.

Q1

5

14R 174 IQ? ?11

’

’

’

Notable in this context is

the significantly increased incidence of second tumors seen with
Hodgekin's disease and tumors of the head and neck, malignancies often
followed by non-specific irrmunosuppression.

211 275
’

A fourth factor which may contribute to the progression of anti¬
genic tumors in vivo is the fact that neoplasms generally develop from
small foci of cells which may not provide sufficient early antigenic
stimulation to elicit a vigorous immune reaction, and therefore "sneak
through" host surveillance mechanisms.

237

Some evidence suggests that

these spontaneous tumors are only weakly immunogenic.

133

Other exper¬

imental evidence exists that, under certain conditions, this lack of
immunogeni ci ty may be due to the coating of cells with substances (such
as sialomucin) which ordinarily prevent recognition.

’

In still

other situations, specific tolerance to the antigens of the tumor or
inducing virus may occur.

223

Once the tumor has developed, progressive growth may be unchecked
or even accelerated by host-specific inmune mechanisms, a phenomenon
known as "enhancement".

Here, TSTA is recognized by the host, but

surveillance is blocked by antigen, antibody, or complexes of the two.
Enhancement may be: (1) afferent, in which TSTA is blocked from stimu¬
lating immunocompetent cells of the host; (2) efferent -- either peripheral
or central -- whereby blocking occurs at the "target" tumor cells or at
the host's effector cells, in both cases preventing effector cells from
"seeing" their targets; or (3) central, in which blocking factors regulate

13

-

-

or inhibit the production of tumor-specific immune mechanisms, pre¬
sumably within lymphoid centers, e,g., lymph nodes and spleen.147,158
Both in vivo and in vitro studies have shown that enhancement may play
a significant role in the host-tumor relationship of many experimental
and human malignancies.

A more detailed discussion of enhancement,

with special emphasis on its significance in human and experimental
models of osteosarcoma, can be found in the "Discussion" section of
this presentation.
Finally, there are some investigators who propose that antigenic
.
. . ,
r
..........
u •
203,259,260,283
tumors persist because of, and not it spite of, host mechanisms.
Prehn

259 260
’
, in particular, has suggested that small amounts of host

response may stimulate tumor growth, while a more intensive cellular
response inhibits it.

While this theory has significanct heuristic

value and may be pertinent to certain tumor systems, there is currently
no in vitro support for it, and it is otherwise largely untested.

259

On the other side of the host-tumor relationship, characteristics
of the neoplastic cells themselves may override the importance of host
defenses.

For example, i ntrinsi cal ly more aggressive tumors (shorter

in vitro doubling time), or those that more readily "shed" antigens, may
grow progressively, the latter presumably through increased blocking
5
activity.
Tumor cells can also reduce their sensitivity to immunologic
attack, by both selective (genotypic) and adaptive (phenotypic) mecha¬
nisms.

These are the processes of "immunoselection" and "antigenic

, . , 106 ,238
modulation , respect! vely.
It is beyond the scope of this paper to comprehensively review all
of the complex variables involved in the process of tumor rejection or
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progression.

An attempt has been made to show that many factors of both

host immunity and neoplastic cells require consideration for an insight
into malignancy, with the understanding that these considerations should
direct future therapeutic efforts.

B.

The Relationships between Chemotherapy, Immunity and Malignancy

The complicated interrelationship between oncogens, immunity, and
malignancy are made even more complex by the addition of chemotherapeutic
agents.

Difficulties are encountered due to the fact that most cancer

chemotherapeutic agents also cause immunosuppression^05,205,208, and in
most cases, this effect is due to the very antiproliferative action
that is at the basis of their anti-tumor activity.

Anti cancer drugs

may inhibit both humoral and cellular responses, usually non-speci fical ly
but under certain circumstances specifically, and these effects are
very dependent on drug dose and schedule, type and amount of antigen,
I nr p op

and time and route of antigen administration.

’

In addition, drugs

may act on neoplastic cells by a variety of means to concomitantly
increase their immunogenicity or susceptibility to immune destruction.

207

At the preclinical and clinical levels, there is substantial evi¬
dence that judiciously used anticancer drugs may act cooperatively, even
synergistical ly, with immunological defenses directed against primary
onr

tumors/

It is important to define the conditions in which this syn¬

ergism is most likely to occur, and to utilize this knowledge thera¬
peutically.

In many cases, however, immunosuppression by chemotherapeutic

agents is unavoidable.

Since most effective cytotoxic drugs may reduce

15-
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the size of a tumor markedly, but are not selective enough to kill the
last tumor cells, host tumor-specific mechanisms are required to effect
a cure.

In these cases, the exploitation of sequential chemotherapy

and immunotherapy seems promising.

198

Thus, chemotherapy-induced immuno¬

suppression may be non-specifically or specifically reversed by adjuvants
such as BCG, or specific tumor-cell vaccines or transfer factor.^7,176
Before these therapeutic approaches can be successfully used, however,
much more needs to be learned of the effects of given agents on both
neoplastic cells and immunologic defenses.

Effects of Chemotherapy on Neoplastic Cells:
The direct tumoricidal effect of chemotherapeutic agents is the
primary mechanism of their anticancer activity, and a vast literature
supports the rationale for their use in di fferent mali gnancies, and
under different doses and schedules.

That they have in certain malig¬

nancies even effected cures is indisputable^’^’^, and these
examples attest to the significance of their cytotoxic potential.
In addition, anticancer drugs have been shown to induce increases
in tumor immunogenicity, and while inadvertent changes may, in part, be
responsible for their therapeutic efficacy, deliberate changes have been
induced to enhance host immunologic "efficiency".

Basically three

approaches have altered tumor immunogenicity, directed to: (1) druginduced alterations of cell metabolism possibly leading to plasma membrane
changes; (2) chemical modifications of the plasma membrane presumably
providing new haptenic determinants or helper (carrier) functions; and
(3) enzymatic treatments of cells leading to increased availability of

16-
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antigenic determinants in the plasma membrane.

207

Fourth, a drug may

increase the immunogenicity of cells resistant to an anticancer drug
through a phenomenon known as "collateral sensitivity".

159

In this

discussion, the inadvertant effects of common cytotoxic agents will be
emphasized, while excellent reviews of deliberate changes in tumor
cell immunogeni ci ty can be found elsewhere.

159 207
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Drugs affecting the control of gene action have altered both cell
metabolism and antigenic expression in a few systems.

Particularly

convincing are studies with steroids used in rat hepatomas
5-bromodeoxyuridine in other experimental models.

44

321

, and

Likewise, 5-fluor-

ouracil (5-FU) treatment in vivo has caused specific changes in TSTA.
In this case, however, it was demonstrated that increased tumor cell
immunogeni ci ty was due to chemical coupling of the drug to antigen or
haptens on the plasma membrane.
While the clinical significance of the above effects is not known
at this time, the importance of collateral sensitivity in particular
malignancies has been well documented.
study

29

159 207
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In one representa ti ve

, it was found that the immunogenicity of L1210 leukemias, as

reflected by transplantabil i ty tests and survival times, was greatly
increased during the development of resistance to 5-[3,3-dimethyl-1 triazenel-imidazole-4-carboxamide (DTIC).

From the eighth transplant

generation onward, a DTIC-resistant subline could not grow in suscep¬
tible CDF-| (DBA/2Cr xBALB/c ) mice, even after the inoculation of 10^
cells, unless the animals were treated with immunosuppressive regimens
of DTIC or cyclophosphamide.

The resistant subline was more sensitive

to treatment with 1,3-bi s [2-chloroethyl 1-1 -ni trosourea (BCNU) than

17-
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parent LI210.

A variety of other reports have also demonstrated that

the increased chemotherapeutic sensitivity of resistant tumor sublines
is dependent on the integrity of host defense mechanisms.

While some

reports suggest that the resistant tumor cells are more susceptible
to host defenses (e.g., via changes of intrinsic growth character!’sties
of the cells)

343

, the majority of evidence has supported the probabil¬

ity that resistant sublines are more immunogenic than the parent cells.

Effects of Chemotherapy on the Immune Response:

In addition to chemotherapeutic cytotoxicity and changes in cellu¬
lar immunogenicity, most anticancer agents are immunosuppressive in
animals and man under a variety of conditions.

While this immunosup¬

pression has been successfully exploited in clinical situations such
as organ transplantation and autoimmune diseases

152 208
’
, in cancer

chemotherapy it is more likely to be counterproductive.

209

Immunosuppression by drugs is usually considered nonspecific in
nature, in that it is the consequence of a pharmacological action, such
as inhibition of cell prol i feration, which may not uniquely affect
immunological systems.

Yet this is not always so; e.g., an anti-proli¬

ferative agent would affect preferentially lymphoid cells stimulated
as a consequence of antigen exposure without necessarily reducing sub¬
sequent capabilities of the immune system to respond to different
antigens, or el iminating non-proliferating "memory" cells.

282

Thus,

a specific effect can be obtained by intrinsically nonspecific pharma¬
cologic means.

The significance of this in cancer chemotherapy will

be indicated below.

207
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As noted in preceding sections, thymus-derived "T-cells" are
considered the most significant of the host immune mechanisms in defense
against neoplasia.

In addition, lymphoid cells derived from bursa-

equivalent tissue ("B-cells") and macrophages play roles of definite
significance in some tumor systems, while being of more equivocal
import in others.

B-cell

synthesis of antibody against certain, but

not all, antigens is triggered as a consequence of an interaction
between certain types of ("helper") T-cells, B-cells, and macrophages.
These complex, and incompletely understood, relationships between
immune cells and their target tumor cells, are represented simply in

c.
, 212
Fi gure 1 .
Both B and T-cells comprise a series of individual cell types at
different levels of differentiation.

Unique antigenic and functional

features characterizing these cell types provide the basis for a great
pop

variety of cellular responses to drugs.

In this context, it is

likely that certain drugs exert selective effects on specific cells
depending in large part on their functional and metabolic status.

Known

examples of this specificity include the selective inhibition of B-cell
populations by asparaginase

21 8

, and that of T-cell populations by pro-

,
104
carbazene.
The timing and schedule of drug treatment may likewise be impor¬
tant aspects of this cellular sensitivity and selectivity.

Indeed,

cytotoxic agents have been divided into groups according to whether
they exert optimal immunosuppression when administered before or after
1 °5
antigen. "

In general, maximum immune depression is obtained when

drugs are given close to the time of antigen administration, suggesting

-18A-

Killing of
tumor cells

Mediators ("lymphokines")
(stimulators and inhibitors)

1) Cytophilie antibody
2) Blocking Factors
(antigen-antibody)
Killing of
tumor cel 1s

T = T lymphocyte
B = B lymphocyte
M = Macrophage

Figure 1
Interaction of lymphocytes and macrophages in tumor destruction.
Adapted with permission from Mitchell (212).
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that the early stages of cell differentiation and proliferatiori are
especially susceptible to inhibition.
While timing is particularly pertinent to experimental systems,
drug schedules apply equally well to human therapeutics.

In this re¬

gard, it would appear that daily treatments with certain drugs suppress
more T-cell responses than humoral responses, whereas the opposite has
been reported to occur with intermittent treatments.

120 209
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That this

may be of extreme practical importance is the evidence that in certain
dispersed malignancies, such as leukemia, B-cell functions may inhibit
tumor growth

213

, whereas in solid tumors humoral factors may cause

enhancement of growth. ^

Clearly, immunosuppression in the former

instance may be deleterious, whereas it might assist tumor rejection in
the latter.
In clinical situations, immunosuppression by a drug may precede
its other anti -prol i ferati ve actions.

In strain-2 guinea pigs, for

example, established delayed hypersensitivity to tuberculin was inhi¬
bited by 2-week treatment with methotrexate at doses which did not
cause leukopenia, overt lymphotoxicity, or anti-inflammatory effects.

119

That unsuspected deleterious immunosuppression may occur has also been
shown in other preclinical and clinical situations.

*

’

The de

novo occurrence of tumors in immunosuppressed transplant patients is
certainly one example.

Another is the earlier and increased incidence

of recurrences and death in patients with bronchogenic carcinoma
treated with long-term cytoxan adjuvant chemotherapy, over patients
treated for shorter periods, or even left untreated.

38
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The evaluation of the interrelationships between drug effects on
tumor, drug effects on immune reactions to tumor, and the anti-tumor
effects of tumor-specific immune mechanisms is difficult to achieve
within a given tumor-host system.

Nevertheless, substantial progress

has been made in the development of model systems designed to sort out
the relative significance of each of these factors, and Mi hi ch

206

has

established a set of general criteria for relevant investigations.
One such experiment cited by Mihich

209

will be briefly summarized.

As few as 10 leukemia LI210 cells grow progressively in DBA/2
mice and in F-| hybrids or backcrosses derived from them.

In these

animals, arabinosylcytosine (AraC) was administered at 10 mg/kg i.p.,
once or twice daily for six days, starting 1,2,3,4 or 5 days after i.p.
inoculation of 106 L1210 cells.

If treatment was begun on days 1 or 2,

only at the total daily dose of 10 mg/kg did AraC induce the expected
50% incidence of 50-day cures, whereas there were no cures seen at
20 mg/kg total daily dose.

If treatment was started on day 5, only

at the total daily dose of 20 mg/kg did AraC induce a 60% incidence of
cures, no cures being seen at the lower daily dose.

Consistent with

this, total-body irradiation prevented the curative effects of AraC
(at 10 mg/kg for six days from day 1) when given on days 1, 2 or 3,
but not when given on days 4 or 5.
These data indicate that shortly after antigenic stimulation, in
the presence of few leukemia cells, the low dose of AraC was sufficient
to eradicate the leukemia without affecting the imnunological response
of the host.

In contrast, high doses of AraC were immunosuppressive

under these conditions, preventing host-dependent defenses from becoming

-21-

evident.

Conversely, when treatment was started late after antigenic

stimulation (in the presence of many leukemia cells), the low doses
of drug were insufficient to eradicate the leukemia, whereas high doses
were chemotherapeutic, being less suppressive to the now ongoing immune
response.

Additional support using L1210/AraC cells (a subline resis¬

tant to AraC) suggested that this subline would not regress unless
rejected by cross-reacting immunity elicited by LI210 during drug
treatment.
It is important to note that some evidence exists that pre-existing
active immunity is usually not severely affected by anti cancer drugs
at therapeutic doses, and that recovery of responsiveness may occur
190

as early as three days after the end of treatment.

90£

’

In addition,

reports have documented that 6-mercaptopurine, a purine anti-metaboli te,
may actually enhance antibody formation in certain situations.

341 342
’

However, as noted above, it is clear that most anticancer drugs, in
addition to their tumoricidal actions, may exert immunosuppressive, and
possibly "immunosynergistic" effects depending on the conditions in
which they are used.

As pointed out by Mihich, "the preservation of

immune reactivity during treatment with anticancer drugs is undoubtedly
as important a goal as is, for example, avoiding gastrointestinal or
bone-marrow toxicity".

209

That such considerations are under-emphasized

in clinical medicine is, in part, a reflection of the lack of available
methodologies in the past to evaluate drug effects on tumor-related
immune mechanisms, and the present paucity of such knowledge relative
to specific drugs.

In the future, cancer chemotherapeutics may be

aided by the knowledge that given drugs are immunosynergistic when used
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under speci fied conditions.

Where immunosuppression is unavoidable,

as noted earlier, efforts are being made at approaches directed to
reversal of that imnunosuppression^^

in order to maximize the

host-drug attack on neoplastic cells.

C.

Adriamycin

Chemistry and Mode of Action:
Adriamycin is an antibiotic of the antracycline group first isolated in 1 969 from cultures of Streptomyces peucetius var. caesius.

15

Its chemical structure resembles that of daunomycin, differing only in
the substitution of a hydroxyl group for a hydrogen atom in the acetyl
radical of the aglycon portion of the molecule.
The biological activity of adriamycin at the cellular level is
thought to be related to its ability to bind specifically with DNA by
intercalation between adjacent base pairs of the double-helical
structure.

84 338
’

By subsequently inducing stereochemical template dis¬

ordering, enzymes involved in both transcription

(DNA-dependent RNA-

polymerase) and DNA replication (DNA-dependent DNA-polymerase) are
nor

inhibited.

These effects are consistent with the in vivo and cell

culture data showing the inhibition of incorporation of precursors into
DNA and RNA, inhibition of mitosis, and induction of chromosomal aber¬
rations.

All are thought to represent the basis of adriamycin's sig-

...
,
...
.. .. 80,204,326
mficant antitumor activity.
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Pharmacol ogy:
The distribution and metabolism of adriamycin have been studied
using tritium-labelling as well as fluorescence techniques.

16 78 336
’ ’

It is rapidly cleared from the blood, and in rodents, high drug levels
are maintained for a long period of time in the liver, spleen, kidney,
lung, and heart.

’

The calculated C x t (concentration x time)

for adriamycin equivalents in all tissues has been demonstrated to be
several times greater

than that found for daunomycin or its metabolites

In man, adriamycin has a distribution comparable to that seen in
rodents, and in both species the drug shows negligible ability to
on

penetrate the blood-brain barrier/ ’

o

Urinary excretion is minimal,

with only 5% of the drug being excreted during the first five days.
Adriamycin is metabolized predominantly by the liver to adriamycinol
and several aglycone derivatives, and approximately half of the drug
is excreted in the bile as adriamycin, another 30% being excreted as
its conjugates.

21

Prolonged plasma levels of adriamycin in patients

with hepatic dysfunction provide the basis of a requirement for dose
deescalation in patients with impaired hepatic function.

20

Antiviral Activity:
The antiviral activity of adriamycin has not been as extensively
evaluated as that of its closely related analogue, daunomycin, but
both drugs have been shown to be inhibitory against a variety of DNA
and RNA bacterial and animal viruses.

Inhibition of bacteriophage

multiplication by daunomycin has been reported by a few investigators

244 278
’
, and this drug protects cells from herpes simplex virus

336
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when given before or a few hours after infection, whereas no effect was
demonstrable when the drug was added four hours after infection, when
the mature virions are thought to appear.

83

Significantly, both daunomycin and adriamycin added to the incuba¬
tion medium at different times before and after infection inhibit the
multiplication of Moloney sarcoma virus (MSV) and the focus formation
typical of this virus in mouse embryonal cells.

46

It has been demon¬

strated that both drugs also inhibit the reverse transcriptase activity
of RNA tumor viruses.

49

The concentrations active on these processes

have negligible effect on cellular proli feration

Clinical Experience:
Since 1969, well over 3,000 patients have been treated with adria¬
mycin alone or in combination with other chemotherapeutic agents for
4
virtually all types of malignancy.
Its activity is wide-ranging,
being most effective against solid tumors but also active against the
hematologic malignancies.
tively with adriamycin:

99

Ten forms of cancer have been treated effecbreast cancer, soft-tissue and osteogenic

sarcomas, cancers of the bladder, lung, thyroid and ovary, Wilm's tumor,
neuroblastoma, Hodgekin's and non-Hodgekin's lymphomas, and acute
leukemias.

The particularly striking efficacy of adriamycin against

osteosarcoma is described in more detail in a later section.
Tumors with encouraging, but more equivocal responses than the
above, include cancers of the stomach, prostate, liver, head and neck,
and multiple myeloma.

The drug has apparently no role in the treatment
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of adenocarcinoma of the large bowel, malignant melanoma and kidney
cancer.

99

Excellent reviews of the current clinical experience with

4 99 232
adriamycin can be found elsewhere. ’ ’

Animal Tumor Studies:
A substantial number of studies have shown adriamycin to be effec¬
tive in delaying tumor progression and increasing survival times in a
variety of transplanted and primary experimental tumors.
32 277
’
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’ * * ' *

Its efficacy and toxicity vary greatly with timing, dose,

schedule and route of administration.

25 45 79
’ ’

Adriamycin is highly active in inhibiting the growth of trans¬
planted Ehrlich acsites tumors in mice, where its effect on increasing
survival times was significantly greater than that of daunomycin.
Likewise, adriamycin proved superior to daunomycin in inhibiting the
growth of transplanted sarcoma 180 tumors in mice.

79

These data support

the higher therapeutic index and generally greater antitumor activity
of adriamycin as compared to daunomycin, especially against solid
tumors, in experimental systems.

79

Of special interest is the striking efficacy of adriamycin on
spontaneous mammary carcinoma of C3H mice, an autochthonous tumor highly
resistant to most chemotherapeutic agents.

Treatment started the

day after tumor implant and repeated every second day for two subse¬
quent cycles strongly inhibited tumor growth and produced a highly
significant increase in survival time.

Treatment with identical doses

administered on consecutive days, however, simply caused a delay in

26-
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tumor development, without increase in survival time over control
animals, and, interestingly an increase in metastatic dissemination.

79 82
*

Toxicity and Effect on Immunity:
In man, toxic effects induced by adriamycin are dose-related pre¬
dictable, and usually reversible.

The most frequent side effects are

dose-limiting myelosuppressi on, mucositis, nausea, vomiting, and
4
chemical phlebitis.
Leukopenia is the primary hematologic toxicity, occurring in over
60% of patients, with a nadir occurring between days 10 and 14.

Throm¬

bocytopenia and anemia likewise occur during this period but their
occurrence is generally less frequent and less severe.

Peripheral

counts usually return to normal by day 21.
Severe mucositis, which limit the administration of adriamycin,
appears to be schedule-dependent.
Another unusual and dose-limiting side effect is cardiotoxi ci ty.
This may involve transient EKG abnormalities or serious irreversible
drug-induced cardiomyopathy.

Analyses by Le Frak et al.

show a

frequency of non-fatal and fatal cardiomyopathy of 0.4% and 1.2%, re¬
spectively.

The incidence of cardiomyopathy is dose-dependent, being
2
markedly increased at total drug doses above 550 mg/m . The measure¬
ment of systolic time interval in patients approaching this dose may be
a sensitive indicator of impending cardi otoxi ci ty.

272

There are a few reported studies in animal systems indicating that
adriamycin may have immunosuppressive effects at certain doses and
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schedules of administration.

45 79 151 241 ?R1

*

*

*

*

These studies can be

broken down as showing effects on either general immune function or
tumor-specific host defenses.
Isetta et al.

161

reported that adriamycin significantly inhibited

the titer of hemolytic and hemagglutinating antibodies in mice immunized
with sheep red blood cells.

These effects were dose-related and were

highest soon after antigen administration.

Likewise, antiviral anti-

bodies responses were abolished by adriamycin in another animal system.
No data are yet available regarding the effect of adriamycin on general
cel 1-mediated immune functions.
At least four reports to date indicate that adriamycin may inhi¬
bit tumor-specific host mechanisms, and that this inhibition may be
less than that caused by daunomycin.

45 7Q ?4l ?ftl

’
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*

As noted earlier, daily doses of adriamycin to C3H mice bearing
mammary carcinomas caused no increase in average survival time (AST),
and, in fact were associated with a significantly increased incidence
of metastatic dissemination in these animals.

That this was perhaps

due to immunosuppression is the evidence for the cumulative toxicity
of adriamycin when administered daily

79

as well as the data suggesting

that T-cell functions may be preferentially depressed with this drug
, , , 120,209
schedule.
A study more pertinent to the present investigation involved the
effects of daunomycin and adriamycin on the growth and regression of
primary or transplantable murine sarcoma virus (Moloney)-induced tumors
in CD-I mice.

45

The experimental design, as discussed more fully in a

45
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later section, is based on the observation that tumors induced by low
viral titers regress spontaneously in 90% of the animals.

Thus, adri¬

amycin's chemotherapeutic activity, as well as its effects on the
mechanisms of spontaneous tumor regression, can be evaluated in this
system.
Treatment with daunomycin before infection inhibited spontaneous
tumor regression, whereas pretreatment with adriamycin caused a delay
and inhibition of tumor growth and no effect in tumor regression as
compared to controls.

Treatment with daunomycin after the infection

(i.v. for eight consecutive days) caused a slight reduction of tumor
size as compared to controls, and a high incidence of tumor recurrence.
Adriamycin treatment after the infection caused a greater reduction on
tumor size than with daunomycin, and tumor recurrence took place later
in time.
While no in vitro tests of tumor-specific cellular or humoral
immunity accompanied these data, they demonstrate that both antibiotics,
in the schedules used, have tumor-related immunodepressive activity.
In addition, the results suggest that adriamycin is probably less immu¬
nosuppressive and/or more tumoricidal in this system than is daunomycin.
In pursuing these possibilities, Orsini and Mihich

241

confirmed

the therapeutic advantage of adriamycin in C57B1/6J mice bearing a
syngeneic EL4 lymphoma.

In addition, the immunosuppressive effects

of the drugs were compared in two different systems using in vitro
tests measuring cellular and humoral cytotoxicity.

While neither system

measured responses to syngeneic tumor - sped fi c antigens, both systems
revealed the drugs to have selective effects, under certain conditions,
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on cellular immunity.

These imnunosuppressive effects were apparently

less than those caused by AraC or methotrexate in the same systems.
In contrast to their expectation, no significant differences between
the effects of adriamycin and daunomycin were seen in the systems used.
No studies to date have reported the effects of adriamycin on
general or tumor-specific immunity in man.

While some evidence exists

in animals, it is not yet clear under what conditions its primary effect
may be on humoral^or cellular^’^’^ immunity.

Finally, no

in vitro data have been obtained supporting the suggestion from in vivo
studies that adriamycin suppresses tumor-specific host immunity.

D.

Osteosarcoma in Man

The term "osteogenic sarcoma" has been variously used by different
authors as the generic name encompassing all primary bone tumors of
mesenchymal origin, or as a specific malignant osteoid-producing entity
originating in endosteal bone.

This distinction is an important one,

since the several entities included in the former classification have
different biologic behaviors, and carry with them unique diagnostic,
therapeutic, and prognostic implications.

Although the more restricted

use of the term will be employed herein, the literature is replete
with references employing the generic usage (or more confusing modifi¬
cations), thus necessitating a brief description of the various entities
from which true osteosarcoma should be differentiated.
The principles outlined for the generic usage of "osteogenic
sarcoma" were first described by Budd and MacDonald

39 194
’
and later
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refined and expanded by McKenna et al.

201

Predicated on their belief

that sarcomata arising in connective tissue of bone "have as their
anlage the stem mesenchymal cell which may differentiate toward fibrous
tissue, cartilage or bone", Budd and MacDonald subdivided osteogenic
sarcoma into three primary categories: fibrosarcoma, chondrosarcoma,
and osteosarcoma, respectively.

McKenna et al. also included as osteo¬

genic sarcoma those bone-producing malignancies arising in Paget's
disease and areas of fibrous dysplasia, tumors induced by prior irra¬
diation, and parosteal (juxtacortical) osteogenic sarcomata.
Defined microscopically, chondrosarcoma is a tumor in which the
dominant cell type assumes a cartilaginous histopathological differen¬
tiation.

Classification of these tumors according to degree of ana¬

plasia reveals a distinct correlation with five-year survival rates,
78% of persons with lowgrade anaplastic tumors and 22% of person with
highgrade malignancies living for five years.

201

Clinically, the patient with a chondrosarcoma is likely to be in
his fourth decade, and three times more likely than the patient with
osteosarcoma to have his primary lesion in the pelvis, jaws, ribs, or
scapulae.

Although the duration of symptoms before treatment may be

somewhat longer than that in osteosarcoma, presenting symptoms and
laboratory findings at diagnosis are substantially very similar.

Meta¬

static disease localizes in a likewise similar manner, although chondro¬
sarcoma is a fundamentally less virulent malignancy than osteosarcoma,
and there is much less tendency to early metastasisAmputation is
the therapeutic mainstay, and five-year survivals in several series
. , ,,
.
. -...
. 69,201 ,239
are consistently about fifty per cent.
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Fibrosarcoma is that malignant tumor of endosteal bone composed
of predominantly interdigitating bundles of spindle-shaped fibroblastic
cells, including varying amounts of collagen.
according to its degree of anaplasia

162

It is usually subdivided

, but according to McKenna et al.

this grading reveals no correlation with survival.

201

These tumors

contain no osteoid; however, the dense collagen of some fibrosarcomata
is so similar to osteoid as to make the differentiation from fibroblastic osteosarcoma one of great difficulty.

298

The incidence of fibrosarcoma is approximately one-fourth that of
osteosarcoma, and the typical patient is in his fourth decade.

201

The

location of the primary tumor, its pattern of metastasis, as well as
other clinical parameters are often similar to osteosarcoma.

Fibro¬

sarcoma generally follows a less aggressive course, however, and fiveyear survivals following amputation are reported as about 30 per cent.00’^0"*
Perhaps the most common entity to be included in statistics per¬
taining to osteosarcoma is osteogenic sarcoma arising in Paget's
disease.

This form of sarcoma may microscopi¬

cally resemble classic osteosarcoma, or may be classified as a chon¬
drosarcoma or fibrosarcoma.^00
In addition to its pathological variation, Paget's sarcoma is
clinically quite dissimilar from osteosarcoma.
nosis of Paget's sarcoma is 60 years

201

The median age at diag-

, and the site of the primary

tumor is much more likely to be the ileum, humerus or skull than in
osteosarcoma.
Sweetnam
years.

308

Longterm survival is rare: all 11 patients of

and all 32 patients of McKenna et al.

201

were dead by five
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Radiation-induced sarcomata are pathologically usually either
osteosarcoma or fibrosarcoma.

201

Strictly defined, these are micro¬

scopically proven sarcomata having arisen in a previously normal bone
five or more years after its having received at least 3000 rads irraro

diation.

Clinically, the patient population is, as expected, quite

heterogeneous, antecedent irradiation being performed for a multiplicity
of malignant, and some benign, conditions.

Five-year survivals are

somewhat better than osteosarcoma arising "de novo" in bone: data from
50 years

.

experience at Memorial Hospital in New York

201

suggest that

after amputation, or amputation plus irradiation, five year survivals
approximate 40 per cent.
Sarcomata arising in areas of fibrous dysplasia are unusual, and
may pathologically be defined as chondrosarcoma, fibrosarcoma or
1 ro

osteosarcoma.

Because of their rare occurrence, they are seldom

included in reports of osteosarcoma, and therefore will not be further
considered here.
The last important, and often confused, entity to be differenti¬
ated from osteosarcoma is the ossifying parosteal sarcoma (juxtacortical osteogenic sarcoma).

Occurring predominantly during the fourth

decade and more commonly in women, these bone-forming tumors develop
on the surface of the bone rather than its interior.

They are charac¬

terized by an indolent growth rate, "pseudoencapsulation", and apparent
growth by longitudinal and ci rcumferenti al extension, resulting in a
large tumor mass encircling, or partially encircling the bone.

201

In addition to age and sex difference between patients with
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osteosarcoma and parosteal sarcoma, the biologic courses of the tumors
are dissimilar.

Parosteal sarcoma is substantially less aggressive,

and metastases, when they occur, are often to the bone.

201

Cure rate

ICO

is high

: McKenna et al. cite 82% five-year survivors, and a "theo-

retical curability" of 100%.

201

Nevertheless, cases of parosteal sarI r n

coma are still often included in series of "osteogenic sarcoma"

,

and their inclusion only serves to confuse and skew statistics meant
to represent responses of classic osteosarcoma to newer therapeutic
modalities.
In differentiation from the above, osteosarcoma in its more re¬
stricted usage is a distinct pathological and clinical entity occurring
mainly in the second and third decades of life, and rapidly progressive
in most cases, with pulmonary metastases and death within two to three
years from diagnosis.

Pathology:
In general, osteosarcoma may be defined as a specialized connective
tissue sarcoma which elaborates neoplastic osteoid from an endosteal
location during the course of its evolution.

Most often, the osseous

tissue arises directly from the sarcomatous connective tissue, but in
rapidly growing areas it may be formed via a cartilaginous intermediary
"I C. A

stage.

Histologically, osteosarcoma is remarkable for its varied

appearance: its microscopic pattern varies considerably from lesion to
lesion and from area to area within the same lesion, depending primarily
on the age of the lesion and its degree of osteogenesis.

162

Relative

to this latter feature, the tumor may be defined radiologically and

34-

-

histologically as either predominantly osteolytic or sclerosing (osteo¬
blastic) in type.

In the former category there may be abundant amounts

of either neoplastic cartilage or fibrous stroma, thus justifying its
histologic subdivision into chondrobl asti c or fibroblastic osteosarcoma,
. .

,

respecti vely.

68

Within non-ossified tissue, the cells may be predominantly anaplas¬
tic, spindle-shaped or round, the latter in lacunae suggesting cartilage
cells.

In ossified areas, there is relatively orderly histologic pro¬

gression according to the age and virulence of the tumor.
described by Jaffe.

162

Initially

This is well

localized to the interior of the

affected bone, the originally pleomorphic tumor cells progressively
spread out from one another, deposit increasing amounts of intercellu¬
lar fibrillar collagenous material, and later osteoid and calcium,
while the cells become progressively more "normal appearing".

249

Pro¬

gressive growth of the tumor causes periosteal irritation and subperio¬
steal new bone formation, later distending the periosteum (causing
"Codman's triangle" on radiographs), and finally disrupting and extend¬
ing beyond the cortex.

I nci dence:
Osteosarcoma is the most common of the primary malignant tumors of
bone.

155 162
5

from 1.4:1

201

There is a definite male predominance, cited variously
to 2:1

162

.

Its peak incidence is in the second and third

decades, as about 75% of all patients in any representative series are
between the ages of 10 and 25 years, with few cases below age 5 and
fewer still above age 40.

Vigorous pursuit of pre-existing bone disease

35-

-

(e.g., Paget's disease) or prior irradiation should be considered before
accepting the diagnosis of de novo osteosarcoma in any person over 50
,
162
years of age.

Localization:
In any large representative series, between half
fifths^

*

knee joint.

68

and four-

6 of the primary tumors are located in the long bones at the
Most of these are at the distal end of the femur, with a

smaller but significant number originating in the proximal tibia.

A

significant number of primaries are also localized to the proximal
humerous and femur, and a fair number are first diagnosed in the pelvic
bones.

There appear to be no absolutely privileged sites, but the spine

and skull bones are rarely involved in the absence of previous irradia¬
tion or pre-existing osteitis deformans.

Clinical Manifestations:
Persistent local pain without other complaints, is the initial
symptom in approximately three-fourths

of patients with osteosarcoma,

while swelling, pathological fracture, or local warmth are presenting
symptoms in a fewer number.

Some patients may complain of anorexia,

weight loss, and rarely, dyspnea or fever, but these are usually late
symptoms.

The average duration of symptoms before seeking treatment is

usually three to four months.^
Of the initial laboratory determinations, only an elevated level
of alkaline phosphatase is helpful diagnostically, although only approx¬
imately one-fourth of patients reveal this abnormality, and then to only

36-

-

two or three times the upper limits of normal.

2 36

In these patients,

levels usually return to normal after definitive treatment, and subse¬
quent elevations are a sensitive index of local recurrence or metastatic disease.

162

Radiographically, osteosarcoma presents a variable appearance,
and its differential roentgen diagnosis is of little more than academic
interest, in that histological confirmation is required for definitive
diagnosis.

Experienced radiologists can normally predict whether a

bone tumor

is benign or malignant in approximately 75% of cases

201

,

and maximum effort should be devoted to making this distinction, and to
determining the best site for biopsy.

"Codman's triangles", often con¬

sidered as diagnostic of osteosarcoma, are encountered in both benign
and malignant tumors, as well as in non-neoplastic conditions.

Like¬

wise, lamellated "onion-skin" or speculated "sunburst" periosteal ap¬
pearances are not pathognomonic for osteosarcoma, although they carry
a high correlation with malignancy.

242

Clinical Course:
The typical course of osteosarcoma, treated or untreated, is a
rapid and relentless one, progressing to pulmonary metastases and
death within two years of its diagnosis.

Indeed, its course is so

aggressive and predictable that Reinberg in 1960 felt justification for
saying that "a case of any age that has recovered from osteogenic
sarcoma has to be regarded as a diagnostic error".

339

A comprehensive review of the literature on over 1400 patients
with osteosarcoma reveals actual five-year survivals, regardless of

37

-

-

primary therapy (operation, radiotherapy, or a combination of the two,
with or without chemotherapy), ranging from 5 to 25.5%.^^,118,236
pointed out by Sweetnam et al .

308

, however, the proportion of patients

surviving five years is a relatively uninformative measure, as survival
curves clearly indicate that mortality is concentrated in the first two
years from starting treatment, and that thereafter the curves flatten
out.

This is reflected in a typical median survival time of about 16

..
308
months.
A definitive prognostic and therapeutic point in the course of
osteosarcoma is the onset of pulmonary metastases.

118

The average time

from onset of symptoms to treatment is about four months

201

, and the

mean interval from starting radiotherapy, radical surgery, or a combination of the two, to pulmonary metastases, is 10 months^
less than five months^0).

’

5 (median,

Death, usually from respiratory failure,

is imminent thereafter, the average period between the discovery of
pulmonary metastases and death being consistently six to seven months

236 308
’

o o/r

(median, six months

).

It is assumed that probably all patients when

first seen have hematogenously disseminated microscopic metastatic
disease

248

, and McKenna et al .

201

describe symptomatic pulmonary meta¬

stases in 10% of patients at initial presentation.
more than 95% of cases with pulmonary metastases.

Autopsy data reveal

201

Only two large series have systematically evaluated their autopsied
patients, and these are somewhat confused by the inclusion of some nonosteosarcoma bone tumors.

’

Summarized, the metastatic patterns

are as follows: bone (osteosarcoma only), 14%; lymph nodes, 30-40%;
pleura, 30%; pericardium, 20%; diaphragm, 18%; kidney, 12%; liver,

38-

-

pancreas and dura, each 8%; adrenal, 6%; thyroid, 4%; and ovary, 2%.
Local recurrences of tumor were found in 50%, and tumor venous thrombi
were found in 14 per cent.

Prognosti c Factors:
Much effort has been devoted to the determination of factors related to prognosis in osteosarcoma.

Schwinn and McKenna

284

break down

the several variables discussed into four categories: those with defi¬
nite, probable, equivocal, and no discernible correlation with progno¬
sis.

The following is a brief update and modification of their findings.
Their first two factors definitely correlating with survival have

already been discussed.

Osteosarcoma has a significantly worse progno¬

sis than chondrosarcoma, fibrosarcoma, or parosteal sarcoma, and a much
better prognosis than Pagetoid sarcoma.
Relative to location, the rare facio-maxi 1 lary primaries have a
better survival rate than osteosarcoma arising elsewhere, and, in
general, those arising in the axial skeleton show worse therapeutic
results than those tumors more distal to the axial skeleton.^8*201 ,2o4
Of the latter, tumors in the distal femur have greater curability than
those in the tibia.^
Not surprisingly, a fourth definite correlate with survival was
stage of disease, persons with metastases to lungs or lymph nodes faring
much more poorly than those with localized diseases.
A final significant "prognostic factor" defined by Schwinn and

39-

-

McKenna is therapeutic intervention -- in their series, persons treated
by immediate amputation, or radiotherapy followed by amputation, survived longer than those receiving no treatment.

284

Of the factors identified as "probably" correlated to survival,
the most interesting is the duration of symptoms.
in at least two previous large series

48 ?01

’

This has been described

-- patients with a short

interval between onset of symptoms and diagnosis have a worse prognosis
than do those with a longer interval.

It has been suggested that this

finding supports the involvement of host immunity in those patients
with a more lingering, indolent prodrome.

118

The size of the tumor at diagnosis also probably correlates with
survival, as a large tumor, other factors being equal, is a bad prog201 284
nostic sign/ ’

236
This, however, has recently been contested/

Factors with an equivocal effect on prognosis include: (1) histo¬
logical grade -- using Broder's criteria for grading the histological
malignancy of the tumor, most Grade I and II tumors (least malignant
appearing) may have a better prognosis, but these grades are very infrequently found.

68

Relative to histological subtype, osteoblastic,

fibroblastic, and chondroblastic tumors all have similar biologic behaviors;0 5

’

(2) sex of the patient -- some reports suggest a

better prognosis for females
substantiated;

1 13 2 84

5

, but this has generally not been

(3) pathological fracture at the tumor site; and

(4) pre- and post-operative serum alkaline phosphatase levels.
Factors reported by Schwinn and McKenna to show no correlation
with survival include: (1) age and (2) antecedent trauma.

The former

40-

-

factor cannot be dismissed easily, however, as a recent careful study by
Ohno and associates^

found age to be the only significant prognostic

variable of ten parameters studied.

In this study, patients fifteen

years of age or younger fared significantly worse than did the older
patients.

Treatment:
As previously pointed out, actual five-year survivals for osteo¬
sarcoma, regardless of primary therapy, have varied from 5 to 25.5
. 61 ,118,236
per cent.
The results of radical surgery, the usual form of primary therapy,
have shown no change from 1946 to 1970.

196

Despite differences in pre-

therapeutic workup, surgical techniques and demography, a comprehensive
review of 1337 patients treated surgically since 1945 has shown consistent five year survivals of approximately 20 per cent.

Of 438 pa¬

tients evaluable at 10 years, 16% were still alive, indicating that the
majority of those patients living five years appear to be "cured".

The

large surgical literature on osteosarcoma and its consistent findings
of about one of five patients surviving five years, justifies using
surgical therapy as the standard against which other therapeutic modali¬
ties must be compared.
The data for radiation therapy alone are difficult to evaluate,
but they seem to indicate that irradiation is the least effective
primary therapy of osteosarcoma.

A fairly extensive literature suggests

that the overall five-year survival after radiation therapy alone is

41-

-

12.5 per cent.

118

Several factors complicate the interpretation of this

response rate; patients with metastatic disease at presentation are
usually considered ineligible for surgery; patients with primaries in
unresectable locations (possibly secondary to Paget's disease) may have
more virulent malignancies^’^ ; some patients may have had other sig¬
nificant medi cal illnesses mitigating against surgery; and finally, true
tumorical doses (6000-12000 total rads) were not utilized in all patients.
A combination of therapeutic modalities has enjoyed increasing and
justified popularity in a variety of malignancies, and osteosarcoma is
no exception.

As noted previously, the onset of pulmonary metastases

marks a definitive point in therapy, the majority of patients revealing
clinical evidence of pulmonary disease within five to nine months of
operation6^’^6, and metastatic disease invariably signifying imminent
death.

229 308
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With this in mind, recent efforts in the treatment of

osteosarcoma have been directed towards two ends: the prevention of
metastatic disease after surgery, and the attack of overt pulmonary
metastases.
The approaches to overt pulmonary metastases have been both sur¬
gical and chemotherapeutic.

Chemotherapeutic approaches have involved

both the systemic administration and local infusion of cytotoxic drugs.
Surgical resection of isolated pulmonary metastases has resulted
in sporadic instances of prolonged survival, but the overall results
o op:

have not been encouraging.

Workers in Japan have investigated the

use of bronchial artery infusions of cytotoxic agents for overt metastases with encouraging, but not statistically significant results.

235

118
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There had been relatively few attempts at systemic chemotherapy for
metastatic disease in osteosarcoma until the last few years.

Neverthe¬

less, with the two exceptions of adriamycin and methotrexate (to be
discussed in the following pages), metastatic osteosarcoma has retained
its reputation as a malignancy resistant to traditional chemotherapeutic
agents.
Historically, the alkalating agents had been most intensively in¬
vestigated, although the numbers of patients were usually small, and a
variety of schedules and doses were not generally employed.

Sporadic

reports have documented partial responses with systemic cyclophosphamide^>252,300 and phenylalanine mustard^#

Overall response

rates with cyclophosphamide were reported as 14.2% (4/23), and with
phenylalanine mustard, 15.5 per cent (5/32).
Mitomycin C was shown to cause regression of pulmonary metastases
in 1961
1971

96 114
’
, but the original enthusiasm for this agent dwindled by

47 304
’
.

Overall, of 76 patients treated, there were 11 responses,

for a response rate of 14.4 per cent.

118

The activity of the vinca alkaloids has been likewise disappointing, vincristine having shown no responses in 21 cases.

Other

agents used with either low response rates or very small numbers to
evaluate include 5-fluorouraci 1 , hydroxyurea, procarbazine, and diethyl
*| I O

triazene imidazole carboxamide.

1^4

’

QQ4

’

Little or no data are

available on the use of many of the alkalating agents, antimetabolites
or nitrosourea drugs.

118

Against this background of minimally promising activity of chemotherapy

43-
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against metastatic disease are the strikingly more effective results
obtained with two drugs, methotrexate and adriamycin.

The former, when

given in high doses and followed by citrovorum factor rescue, has caused
tumor regression in four of ten patients with metastatic osteosarcoma
I

followed from one to more than eight months.

ro

At the time of publi¬

cation, complete regression of pulmonary metastases had occurred in two
patients, and persisted in one of these.

In contrast, methotrexate
r

alone or in conventional doses has failed to show any response.

q O1Q

’

Finally, Cortes et_al_.60 have reported objective regression of
pulmonary metastases in 7 of 17 patients treated with adriamycin and
followed from 4 to more than 20 months.

Metastases shrinkage of over

50% was seen in five patients, and in one there was a complete remission
Although all patients treated showed signs of toxicity and two patients
succumbed to adriamycin-associated cardiomyopathy, the data clearly
revealed the effectiveness of adriamycin in treating metastatic disease,
and stimulated research into the use of adriamycin as an adjuvant to
surgery in the prevention of metastases.
Adjuvant chemotherapy is the most promising of the several methods
used to approach the second, and more important problem in the treat¬
ment of osteosarcoma -- the prevention of metastatic disease.

Consider¬

ing that hematogenous pulmonary metastases are present in the majority
of patients at the time of diagnosis

35 164
’
, three other approaches

have also been tried, including the pre-operative ligation of the veins
draining the tumor
and immunotherapy.

site
296

1 75

, prophylactic irradiation of the lungs

57 231
’

The significant roles of tumor immunity and

immunotherapy in osteosarcoma will be discussed in a later section.

44-
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While the pre-operative ligation of the veins draining the tumor
site has not resulted in significantly prolonged survival or fewer
post-operative metastases

35

, there have been many proponents of pro¬

phylactic pulmonary irradiation in addition to amputation.

These have

included both pre- and post-operative radiation, at varying intervals
from surgery, and with varying doses of irradiation.

Most reports

indicate only a slight advantage for the addition of radiation to ampu11 o

tation.

Nevertheless, at least one promising report, showing delayed

onset of pulmonary metastases after pre-operative radiation plus amputation, suggests that this is one modality to be pursued further.

231

Finally, two chemotherapeutic approaches, one using high dose
methotrexate with citrovorum factor rescue, and the second using adriamycin, have shown strikingly effective activity in the prevention of
pulmonary metastases.

Their use as adjuvants is based on substantial

experimental cytokinetic evidence that the proportion of neoplastic
cells destroyed by a given treatment should be significantly greater
in micrometastases than in clinically apparent metastatic disease.

281

In the first chemotherapeutic method, high doses of methotrexate
are given in conjunction with vincristine, followed two hours later by
12 intravenous doses of citrovorum factor "rescue".

164

This regimen,

using increasing doses of methotrexate given every three weeks, signi¬
ficantly reduced the post-operative incidence

of pulmonary metastases.

Although only 12 of the 20 patients studied had "classic" osteosarcoma,
11 of these were free of metastases from 6 to 27 months.
In the adriamycin regimen, six three-day courses (30 mg per square

-45

meter daily) were administered (following surgical healing) to 21
patients with "classic" osteosarcoma.6^

Of thirteen patients treated

with amputation and no protocol deviation, twelve were completely free
of disease at periods from one to 31 months after operation.

An update

of these data reported two subsequent relapses, such that 10 of the 13
patients remained disease-free at a median of 19 months post-operatively,
and 3 to 34 months after the discontinuance of chemotherapy.

40

Although

admittedly these data may only signify an inhibition of tumor growth
and a delay in the appearance of metastases, another report supports the
probability that adjuvant chemotherapy is actually preventing the occurrence
of metastatic disease.

305

At least two other recent prospective,

controlled studies including adriam.ycin in a multiple drug adjuvancy
protocol have substantiated this assessment.

340 305
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Etiology and the Role of Tumor Immunity:
Although there have been several theories of causation for osteosarcoma, including antecedent trauma

and genetic origins^

, there

•k

is abundance evidence to suggest a viral etiology.

Before reviewing

the evidence, it is pertinent to first briefly review the requirements
for proof of causality and to site the limitations imposed by these
requi rements.
As originally posed by Koch in 1891, there are three essential
conditions which must be fulfilled in order to establish a causal rela¬
tionship between a suspected infectious agent and a particular disease.
* REFERENCES: 1 -3,22,23,27,28,54-56,92-94,107-109,1 11 ,125,128,135,137,
138,167,1 72,219,225 ,226 ,254,263-265 ,271 ,273,332,333

46-
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In general terms these are as follows: (1) the micro-organism must be
observed in all cases of the disease in question; (2) it must be isolated
and grown in pure culture, and (3) the micro-organism so isolated should
reproduce the disease in other susceptible animals.

Today a fourth

criterion is generally recognized -- the demonstration in the infected
host of circulating humoral and/or cellular immunity specific for the
organism in abnormally high concentration, or an abnormally high specific imnunity to the infecting agent in a recently recovered host.

330

Therefore, supporting evidence that viruses cause several human
cancers has been gathered in several ways.

270

One approach has been to

search for virus particles, viral precursors, and vi rus-speci fi c nucleic
acids in human tumor biopsy samples and cultured tumor cells.

A second

method is to experimental ly induce tumors by inoculation of human tumor
material or putative human oncogenic viruses.

Resulting animal tumors

are then examined for candidate human viruses.
Data suggesting a viral etiology for human cancer have also accu¬
mulated by monitoring the ability of a virus to transform cells in
culture.

These transformed cells grow indefinitely in tissue culture,

lose qualities of contract inhibition, alter their surface properties,
and are often capable of inducing tumors.
Finally, immunologic methods have been used to determine the pre¬
sence of tumor specific antigens and anti-virus antibodies in indivi¬
duals with cancer, their families and associates, and in large populations
of people.

Immunology has been a particularly powerful tool in estab¬

lishing a viral etiology for human malignancy, in that tumors induced

m

.

■

n
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by the same oncogenic virus, even in unrelated animals or when producing
histologically different malignancies, share at least one common tumorspecific anti gen. ^

As previously noted, this is in striking contrast

to tumors induced by the same chemical carcinogen.

171 237
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In summary, then, while there is substantial evidence for a viral
causation of some human malignancies, much of this evidence is indirect,
depending on the host's recognition of, and response to, virus or vi rally
determined antigens.

Merely the presence of virus does not establish

its causal role and yet direct proof -- to induce cancer by injection
of the virus into healthy human subjects -- is morally and ethically
prohibited.

Nevertheless, even in bacterial non-tumor systems, the

causal role of a particular micro-organism is sometimes justifiably
adduced without complete fulfillment of all Koch's postulates, when the
overwhelming preponderance of evidence presents a very high degree of
...... 330
probability.
Two groups of viruses have been consistently associated with natu¬
rally occurring cancer: oncornavi ruses containing single-stranded RNA,
and herpesvi ruses composed of double-stranded DMA.

Herpesvi ruses have

been strongly linked to the causation of Burkitt's lymphoma, nasopharyngeal carcinoma, and cervical carcinoma.

Oncornavi ruses, especially

C- and B- types, possess reverse transcriptase, which enables DNA to be
produced on an RNA template, reversing the usual direction of informa¬
tion.

This DNA intermediate is then integrated into the host genome,

causing neoplastic transformation by as yet unknown mechanisms.

297

B-type particles and reverse transcriptase have been associated with
human breast cancer

218

, and several components of C-type viruses as

48-

-

well as reverse transcriptase have been isolated from patients with
acute leukemia.

1 24

It is predominantly this latter group of oncorna¬

viruses which have likewise been associated with human osteosarcoma,
the evidence for which follows.
Electron microscopic examination of thin sections of human osteo¬
sarcomata1 00,109 , their derived tissue culture cells106,226 anc| ce-j-|
culture supernatants107,109,26^ have revealed C-type RNA particles.
The incidence of these findings has varied; e.g., Gyorkey et al.

1 35

found nine of 12 tumor biopsies positive for the virus, whereas Morton
et al.

226

could not visualize any in the specimens from six sarcoma

patients, yet visualized them in tissue cultures of the same tumors.
The particles were similar to the tumor viruses first described by
Bernhard

24

, with an outside diameter of 85-90 millimicrons, appearing

singly throughout the cytoplasm or in groups within cytoplasmic vesi¬
cles, and occasionally seen in the dumbbell shape of many murine leukemia and sarcoma viruses.

2 26

Cell-free extracts of human osteosarcomata, many containing C-type
viral particles, when inoculated into hamsters

, guinea

pigs26*1, and mice107 have reproducibl.y produced osteogenic sarcomata
in these animals.

Tissue sections of these animal tumors have then been

shown to contain C-type viral particles.

108

Conversely, several studies have shown that murine sarcoma virus,
strain Moloney (MSV), is capable of successfully transforming and replito

eating in human diploid cell lines in culture.

99

*

’

99
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’
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Similar

results have also been obtained with feline leukemia and sarcoma vi¬
ruses.111,107

The results with MSV include the early and easily

49

-

-

reproducible transformation of some human embryo cell strains, and the
interesting finding of a shift of viral tropism, once viral transforma¬
tion of the human cells has occurred.

Thus, relative to its trans¬

forming function, the original double tropism (murine-human) of the virus
shifted to an exclusively human one, retaining its transforming effect on
fresh human cell cultures with excellent reproduci bi 1 i ty.

22

Additional evidence for the etiology of an infectious agent is the
remarkable familial incidence of osteosarcoma.

133 254 273
’
*

While ori¬

ginally this suggested to investigators the possibility of a genetic
origin for osteosarcoma

254 273
5
, as early as 1935 the question of an

adjuvant role of an infectious agent was considered.

273

four offspring in the same family have been afflicted.

As many as

138

Finally, consistent with the intimate association of viral lyinduced tumors and immunological methods, there is abundant evidence
to suggest the presence of a sarcoma specific antigen(s), the probabil¬
ity that this antigen is virus-related, and that host responses to this
antigen may play a significant role in the in vivo destruction of
tumors.
A variety of immunological techniques have revealed the presence
of at least one antigen which is specific for sarcomas.
has been detected on the cell surface

This antigen

27 55 333
’ ’
and in the cyto-

plasm^’^’^’^’^3 of malignant cells, and host response has been
,
,, , 54-56,125
. ,
, 27,92-94,219,225,226 ,263,265 ,271 ,332
both cellular
and humoral. ’
*’**’*’
Using indirect immunofluoroescence (IF), common anti-sarcoma antibodies
have been found in the sera of essentially all sarcoma patients against

50-
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o "7

o or

o

nr

autochthonous or allogeneic tumor lines. 7

in addition, approx¬

imately 85% of close family members and 90% of close, unrelated associqo

ates have anti-sarcoma antibodies as determined by IF.

nor

’

00£

’

Sera

from unrelated normal blood bank donors have a variable incidence of
positivity, generally reported as being between zero and twenty-nine
per cent.

Antibodies cytotoxic to human sarcoma cells

have also been reported in patients with sarcomas.

332

That the above

anti-sarcoma antibodies are specific for sarcoma cells (of various
histological types) has been convincingly demonstrated -- the sera are
non-reactive against a wide variety of other human cell lines.

219

Cellular immunity in sarcoma patients is likewise sarcom-specifie.

54-56 1 25
5

In one study reported by Cohen et al.

55

, peripheral

blood lymphocytes from 14 of 18 patients with several histological
types of sarcomata were cytotoxic to an allogeneic osteosarcoma cell
line, but not to fibroblasts from the same patient.

Lymphocytes from

melanoma patients were consistently non-reactive.
In keeping with the common antigenicity of vi ral ly-induced tumors,
these immunologic data are perhaps sufficient in themselves to impli¬
cate a virus in the etiology of human osteosarcoma.

To summarize these

results, it may be instructive to briefly review one elegant study
reported by Moore and Hughes.

In this study, 42 sera from 31 sar¬

coma patients, 17 sera from 11 patients with various carcinomata, and
34 sera from 18 non-tumor bearing control patients were tested by IF
against 38 tissue culture lines, including those derived from sarcomas (16),
carcinomas (7) and other tumors (2), embryonic tissue (8) and normal
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adult tissues (5).

In addition, IF tests were done to detect anti¬

nuclear antibodies (ANA) and smooth muscle antibodies (SMA), and sera
were tested for HL-A antibodies by microcytotoxicity tests against a
panel of 22 lymphocyte preparations.
Their results, simply put, included the following:

(1) There was

a significantly higher incidence of anti-sarcoma antibodies (ASA) in
sera from sarcoma patients than in carcinoma sera or sera from controls;
(2) sarcoma sera showed no^ reactivity against 21 of 22 other human cell
lines, including all those of embryonic origin; (3) sarcoma sera had
significantly lower incidence of ANA and HL-A reactivity; and (4) sar¬
coma sera had a slightly increased incidence of SMA's.
These results dramatically illustrate the specificity of the sar¬
coma antigens and help elucidate their nature.

Failure to demonstrate

HL-A reactivity, in addition to the presence of authocthonous anti¬
tumor activity, in the sarcoma sera strongly suggests that the antigens
are not intra-cellularly expressed HL-A antigens.

The lack of reacti¬

vity against cell lines recently derived from human embryonic tissue also
minimizes the possibility that these antigens are of a fetal type.

In

addition, the immunologic specificity of the reactions renders "anti¬
genic conversion" by exogenous virus or mycoplasma unlikely, and these
conclusions were also supported by the authors' inability to isolate
mycoplasma from the tissue cultures.

Finally, although these may

represent tissue-specific antigens which may be detected in vitro

202

,

as there was a slightly increased incidence of SMA in the sarcoma sera,
a more interesting and likely possibility is that the antigens repre¬
sent intracel 1 ular products specified by an endogenous virus.

Although

52-
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no electron microscopic evaluation of the malignant cells was performed,
these exacting immunologic data provide a convincing complement to the
previously cited data supporting a viral etiology for osteosarcoma.
That the host response to osteosarcoma in man is significant for
tumor destruction in vivo has been suggested by a wide variety of
in vivo and in vitro correlates between the clinical progression of
tumor and the hosts' immunological state.

At the outset, it is impor¬

tant to clarify that the specific cellular and/or humoral mechanisms
important for the destruction in vi vo of osteosarcomata have not yet
been completely defined, and that some of the data supporting these
mechanisms are in conflict.
Studies of cellular immunity in patients with osteosarcoma have
reported varied results, some studies indicating lymphocyte competence
on?

in all stages of disease
just the opposite.

47 322
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, while others have reported apparently

These apparent differences are somewhat cor¬

rected when disparate methodologies are compared and clinical stage is
taken into consideration.
et al.

202

and Golub et al.

For example, whereas studies by McMaster
130

both show normal in vitro PHA-responsi ve-

ness of lymphocytes in sarcoma patients, the latter study revealed
decreased conconavalin A responsiveness in lymphocytes from these same
patients.

Golub et al . conclude from these data and those on patients

with many other types of malignancies that con A is both a more sensi¬
tive index of lymphocyte proliferation defects and a better in vitro
correlate of in vivo immunologic state in cancer patients.

Thus,

added credence is given to other reports of decreased lymphocyte mitogen
responsiveness in sarcoma patients.
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Del ayed hypersensitivity reactions (DHR) to common microbial anti¬
gens and DNCB, in vivo tests of non-specific cellular immune competence,
especially "recognition" competence

130

, are more easily interpreted.

In general, while at least one study reported normal delayed hypersensitivity reactions in sarcoma patients

253

, all studies have shown sigQ "I

nificantly decreased DHR in patients with advanced disease.

I on

’

or o

’

That this may be important prognosti cal ly was shown by Eilber and
Morton

91

tation.

, who correlated DHR with clinical state before and after ampu¬
In their study, 93% of DNCB-negati ve patients were either

inoperable or developed early post-operative recurrences, whereas 92%
of DNCB-positive patients were free of disease at six months after
surgery.
In vitro studies of humoral immunity have shown similar results.
Cytotoxic antibodies detected in vitro are assumed to be significant
for in vivo tumor destruction.

332

In addition, antibodies detected by

IF in sera from sarcoma patients have been significantly depressed in
patients with metastatic disease

219

, and serum factors blocking cell-

mediated immunity have been found in 83% of patients with progressi vely
enlarging sarcomas.

54 5fi 145
’ ’

Finally, perhaps the functionally most important evidence clari¬
fying the significance of host immunity in osteosarcoma has come from
studies of immunotherapy.

Essentially all the main forms of immuno¬

therapy have been attempted, with varying amounts of vigor and with
varying degrees of success; including, non-specific stimulation with
BCG, passive transfers of specifically immune antibody, lymphocytes and
transfer factor, and active immunization with various forms of tumor
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cell vaccines.88,190,197,296,329

-

Active immunization with BCG and

autologous tumor cells has induced in vitro heightened immune responses
against tumor associated antigens, with occasionally beneficial therapeutic results.

224

A recent clinical trial using irradiated fresh

autochthonous tumor cells as a vaccine adjuvant to surgery reported
four of five patients disease-free at 20-31 months post-operatively.
Though of small sample size, this study has revealed significant pro¬
longation of disease-free intervals in these patients, and underscores
the other evidence supporting the substantial importance of tumorspecific host mechanisms in osteosarcoma.

E.

Animal Models of Osteogenic Sarcoma

Characteristics of an Ideal Animal Model:
An ideal laboratory model for osteosarcoma, in keeping with the
character!'stics of the human tumor described in the previous discussion
should include the following:

(1) the tumor should arise "spontan¬

eously", or be induced reproducibly by a virus; (2) it should initially
be well localized for surgical ablation and/or local therapeutic mani¬
pulation; (3) its pathological nature should include osteoid-producing
malignant cells; and (4) it should have a clinical course similar to
the human disease, with a similar incidence and distribution of meta¬
static disease.

A final consideration is that reproducible assays

must be -available for this model to permit evaluation of the immune
response evoked by the tumor.
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Historically, animal models of osteosarcoma have included spon¬
taneously arising tumors'^, tumors induced by external irradiation^
or injection of radioactive isotopes
carcinogens

220

53 156
’
or oncogenic viruses.

, and tumors caused by chemical
A great variety of animal

species have been used.
Spontaneously arising osteosarcomas have been observed in dogs,
but only very infrequently.

3G

Radiation-induced sarcomata, while very

reproducible, produce only weak tumor-specific antigens, are poorly
localized, and require long latency periods.

160 220
’

Chemical carcino¬

gen-induced tumors have greatly enhanced knowledge of tumor immunology
in animals, but most importantly lack the common antigenicity seen in
virally-induced tumors, as noted previously, and therefore lack a
fundamental characteristic of human osteosarcomas.
Models for osteosarcoma have included tumors induced by both DNA
(SV-40)

75 76
’ 0 and RNA viruses in mice, hamsters and rats.

produced tumors when inoculated by intravenous

75,76

Viruses have

, intra-muscu-

,141,199
, 102,141,199,217,286
. .
..
,121 ,295
. . .
.... ,
lar
*
, intraperitoneal
and intra-tibial
routes.

117,160

MSV - Mouse Systems:
By far the most extensively studied animal models are the Moloney
Sarcoma Virus (MSV)-induced tumors in mice.

MSV is a known oncogenic

RNA virus closely real ted to the murine leukemia virus (MLV) and
sharing antigens with other closely related viruses of Friend and
Rauscher.

52,101,150

The induced tumors are highly antigenic, although

56

-

-

there are different neoplastic and immunologic responses to the inocu¬
lated virus both between different strains of mice ^ and ratsJ^
Thus, young BALB/c, C3H and (NZW x NZB) F -j (B/W)

strains of mice all

develop rapdily enlarging soft-tissue tumors, and while tumors regress
in C3H mice, they grow progressively in BALB/c and B/W strains, and
each strain shows unique immunologic responses.

1 26

The induced lesions

also have been shown to vary substantially by different routes and
doses of virus administration.^
The most thoroughly evaluated MSV model is the sarcoma induced by
intramuscular inoculation of MSV into BALB/c mice.

In this system,

mice injected with MSV by three to four weeks from birth invariably
develop tumors within approximately 10 days, which usually grow progressively and kill the animals.

102 141 199 21 7
’
’
’

Older mice injected

with MSV likewise develop tumors, but these usually reach a maximum size
of 10-15 mm and then regress.

102

Immunosuppression of adult mice by

X-irradiation^, ALS ^ or cortisone treatment^, or chemotherapy
with cyclophosphamide

101

or daunomycin

creased incidence of tumor

45

, causes a significantly de¬

regression.

Pathologic evaluation reveals these tumors to be rhabdomyosarcomas.

217 247
’

The sarcomas contain and release virus as demonstrated

by electron microscopy
induce tumors in vivo

121

247

, the ability of cell-free tumor extracts to

, and focus formation in vitro.

139

Immunologic studies in this system have been extensive, and will
be discussed in greater detail later.

Suffice it to say that a variety

of immunological techniques have been used to demonstrate the presence
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of anti-viral antibody, as well as both tumor-specific cellular and
humoral immunity in vitro throughout the course of these tumors.

Both

in vi vo and in vi tro studies, therefore, have clearly demonstrated
the significance of tumor immunity in the murine model for osteogenic
sarcoma.
Relative to the ideal animal model criterial proposed above,
however, the MSV-BALB/c tumor system lacks two essential components:
(1) the BALB/c tumors, consistent with other MSV-induced tumors in
mice

169

, are myosarcomas, lacking any ability to produce osteoid; and

(2) the incidence of metastases in this system is low, and metastases
are not distributed in a pattern similar to the human disease.

In

addition, the small size of the animals makes effective surgical inter¬
vention difficult, and many animals often need to be sacrificed for
sufficient serum and/or lymphocyte collection for in vitro immunological
studies.

MSV - Rat Systems:
Factors such as these have led a few investigators to pursue an
mcw • j
a
4.
,
r
.
51,121 ,160,169,295,320
MSV-mduced rat model for osteosarcoma. *
’
*
ting reports exist as to the oncogenicity of MSV in rats; Ting

^-i.
Conflic-

r

320

states

that MSV rarely produces tumors in intact newborn rats, and Kano-Tanaka
et a!.

169

report that tumor induction in rats requires doses of the

virus ten thousandfold higher than those in mice.

These studies reveal

the importance of the route of virus administration, as Ting used intraperitoneal and Kana-Tanaka et al . used either intraperitoneal or subcutaneous-intramuscular virus inoculation.

Ikemoto and Yamamoto

160
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however, report an 87.5% incidence of tumors when MSV is injected
directly into the marrow of the tibia of newborn Wistar-Lewis rats.
One uniform finding among these studies and those of Chesterman
et al.

51

, Soehner et al .

295

and Fuginaga et al.

1 21

, is that rat sar¬

comas induced by Moloney Sarcoma Virus, regardless of route of inocu¬
lation, are almost invariably osteogenic in nature.
contrast to the myosarcomas induced by MSV in mice.

This is in marked
169 217 247
5
’

Con¬

sistent with mouse models though, was the preliminary evidence that
suggested significant tumor immunity in these rat models for osteogenic
sarcoma.

This evidence included the increased incidence of sarcomas

in thymectomized rats

320

, and the total inability of investigators to

induce tumors in the mature animals.^
Of the rat models for osteosarcoma, that described by Ikemoto and
Yamamoto seemed to be the most promising, and it motivated Friedlaender
and Mitchell at Yale to pursue this system further.^7
their work will be described briefly.

The results of

Following intra-tibial inocula¬

tion of MSV within 24 hours of birth, 97.7% of the animals developed
localized tumors defined histologically as osteogenic sarcomas.

Of

those rats which could be evaluated, 77.9% had progressively enlarging
masses and 22.1% had regressing tumors at the time of sacrifice or
shortly after death.

Although a detailed incidence study of metastases

was not done, metastases were frequent in progressor animals, and these
were most commonly to lungs.
Tumor-specific cel 1-mediated cytotoxicity (CMC) was evaluated
and found to be present in all animal groups tested from 19 to 88 days
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of age.
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Since a single homogeneous tumor cell pool was not used through¬

out the experiments, however, changes in CMC did not necessarily reflect
the changes of in vivo CMI during the course of the disease.

Serum

factors modifying this cell-mediated immunity (either "blocking" or
"helping" factors) were also seen, and these were roughly correlated to
the animals' clinical status.
Thus, an animal model has been found which very adequately ful¬
fills the criteria previously proposed for correlation with human
osteosarcoma.

Intra-tibial inoculation of a virus has reproducibly

produced well localized osteoid-producing tumors in newborn rats, and
these tumors very readily metastasize in a pattern apparently similar
to the human disease.

While these data are preliminary, they suggest

that further study of this model may help untangle the complex questions
posed by osteosarcoma, including its relentlessly progressive nature
and its alteration by immunological factors.

F.

Summary Statement of the Goals of the Present Investigation

Osteosarcoma is a devastating and therapeutical ly resistant malig¬
nancy of young people, progressing to pulmonary metastases and death
in 80% of patients within two years of its diagnosis.

Abundant evidence

supports a viral etiology for this tumor, including a common antigeni¬
city for several histological types of sarcomas.

Tumor-specific

immune mechanisms may play a significant role in preventing the usually
rapidly progressive course of osteosarcoma.
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Evidence has been reviewed that suggests that immunosuppression by
chemotherapeutic agents may be counterproductive and clinically signi¬
ficant in cancer therapy.

Thus, anti cancer agents are seen to be both

tumoricidal and potentially immunosuppressive.

Adriamycin is a rela¬

tively new anti cancer drug with a broad spectrum of tumoricidal activi¬
ties, but there is a paucity of data relative to its effects on tumorspecific immune mechanisms.

Its tumoricidal action against osteosar¬

coma has been particularly striking, as it has postponed (and possibly
prevented) the onset of metastatic pulmonary disease, and probably
increased survival times.
An initial investigation has suggested that an MSV-induced rat
osteosarcoma may be an ideal model of the human disease.

Initially

localized, the primary osteoid-producing tumor metastasizes and is
rapidly fatal to most infected animals.

Assays have been used which

document the presence of tumor-specific cellular and humoral responses
in tumor-bearing hosts.
With these considerations in mind, the present investigation was
designed to fulfill three general goals:

(1) To substantiate the

extent of similarity of the rat osteosarcoma model to osteosarcoma in
man, by evaluating its course, histology, and further documenting its
incidence and distribution of metastatic disease; (2) to study the immu¬
nobiology of this tumor, with an emphasis on tumor-specific cellular
responses throughout the course of disease; and (3) to evaluate the effects
of adriamycin chemotherapy on the course and immune responses of tumor¬
bearing animals.
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Materials and Methods

A.

Rats

Pregnant Wistar-Lewis rats, an inbred strain, were obtained from
Charles River Breeding Laboratories (Wilmington, Mass.) at 18 to 20
days' gestation.

Their litters, ranging from six to fifteen pups, were

inoculated with virus within 24 hours of birth.

Males and females

were caged together until six weeks of age, and animals were weaned at
20 days.

B.

Virus

A Moloney strain of murine sarcoma virus (MSV-M), (hereafter re¬
ferred to as MSV) was obtained through the courtesy of Drs. J.B. Molo¬
ney and J. Gruber of the National Cancer Institute.

This was propa¬

gated in BALB/c mice and harvested at 14 days by Mr. Richard Murahata
according to the method of Moloney.

215

A virus suspension was prepared

as 1 gram-equivalent/ml. and stored at -70°C until ready for use.
After rapid thawing, the virus was iirmediately inoculated into the
newborn rats.

C.

Infection of Rats

Virus inoculation was performed according to the method originally
described by Ikemoto and Yamamoto.After cleansing the left hind
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1 imb of a newborn rat with alcohol, a 27 gauge needle was inserted into
the marrow cavity of the tibia through the knee joint (Figure 2).

A

0.025 ml aliquot of the virus suspension in Eagle's Minimal Essential
Medium (MEM, from GIBCO, Grand Island, New York) was then injected.
Control animals received identical inoculations of MEM alone.

Figure 2
Technique of Virus Inoculation
See text for explanation.

D.

Treatment

Treatments were performed i.p. with adriamycin hydrochloride dis¬
solved in normal saline.

Experimental groups were administered doses

of 1 mg/kg/day or 2 mg/kg/day for three consecutive days.

Control
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animals were given comparable volumes of normal saline.

Treatment was

started at 10 days of age when approximately 90% of the animals in all
groups had palpable tumors.

E.

Clinical Evaluation of Tumor Size

Tumor growth and regression were evaluated by measuring with ver¬
nier calipers the greater of two transverse diameters of the left
lower extremity.

Uninfected control animals were also measured in order

to discern the amount of increased diameter due to normal growth of
these young animals.

F.

Pathology

At the time of death or sacrifice for assays, the tumor site, re¬
gional lymph nodes, lungs, liver and spleen were grossly inspected.
Portions of these tissues were preserved in 10% formaldehyde.

Hard

tissue (tumor and bone) was subsequently subjected to decalcification
in serial baths of 5% formic acid, and all tissues were then embedded
in paraffin.

Tissues were stained with hematoxylin and eosin and/or

Masson's trichrome preparation.

G.

Radiology

At various times prior to death or at sacrifice, radiographs to
illustrate bony structures were taken of both normal and tumor-bearing
animal s.

64-

-

H.

Evaluation of Cell-Mediated Immunity

Target Cells:
The primary target cells for assay of cell-mediated cytotoxicity
were from a single homogeneous line of tumor cells derived from a WistarLewis rat (MSV/WL) and kept in tissue culture through serial passage.
Originally, a growing tumor was sterilely removed from a donor rat,
minced with scissors in MEM, and filtered through several layers of
fine-mesh gauze.

After centrifugation of the filtrate at 900 rpm for

10 minutes, the cells were washed twice in MEM and resuspended in a
Waymouth's medium (GIBCO) solution including 30% fetal calf serum (FCS),
1% each L-glutamine, penicillin and streptomycin, .15% mystatin, and
buffered to a pH of 7.4 with NaHCO^.

After successful adherence and

propagation of these original cells, the medium was changed in serial
passages to an RPMI-1640 (GIBCO) solution containing 10% FCS, 1% each of
penicillin and streptomycin, .10% mystatin and 1% tylocine, the latter
to inhibit growth of mycoplasma organisms.
In addition to the MSV/WL cells, normal fibroblasts from WistarLewis rats were obtained from explants of rat skin of uninfected
animals as described above for the tumor cells, and grown in tissue
culture.

Tumor cells from a mouse leukemia P383D1 were also used as

target cells for two experiments, and these were obtained originally
from Mr. Richard Murahata who had maintained them in tissue culture.

173

All cells in culture were maintained in 30-ml Falcon plastic tis¬
sue culture flasks (Falcon Industries, Oxnard, Calif.).

Tissue cultures
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were maintained in a 37°C 5% CO^ atmosphere, and media were changed
twice weekly and as necessary.
At the time of assay or serial tissue culture passage, cells were
harvested by subjecting them for 10 minutes to 2.5% trypsin diluted
1:10 with a solution of phosphate buffered sal ine-ehtylenedi amenetetraacetic acid (PBS-EDTA).

After the majority of cells were floating

free in solution, FCS was added in a volume equivalent to 30% of the
total volume.

The suspension was centrifuged at 1000 rpm for 10 minutes,

and then either resuspended in medium for tissue culture, or counted,
viability determined, and prepared for assay.
by the trypan blue dye exclusion technique

31

Viability was determined

, and was consistently

found to exceed 95%.

Serum:
At the time of assay, blood was obtained in one of two ways: when
the animals were young (generally less than 35 days), groups of three
animals were exsanguinated by jugular vein incision and their blood
pooled, whereas older animals often supplied sufficient quantities
through scalpel nicks made in the lateral tail veins.

The blood was

obtained after cleaning animal surfaces with alcohol, and following
heat inactivation of the serum complement in a 56°C water bath for
thirty minutes, the pooled serum was centrifuged at 2000 rpm for 20
minutes.

Finally, prior to assay, sera from both tumor-bearing and

control animals were further purified by filtration through 45y minipore
f i 1 te rs.
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Lymphocytes:
Peripheral blood was used as the source of effector cells, and
lymphocytes were isolated by centrifugation of diluted blood over a
Fi col 1-Hypaque density gradient.

33

Staining of the effector population

with Wright's stain showed it consistently to be composed of 90-93%
lymphocytes, 2-5% polymorphonuclear leukocytes, 3-6% monocytes, and a
variable small number of red blood cells.

When red blood cell contami¬

nation occasionally approached 5%, these cells were removed by treatment
with a tns buffered-ammoni urn chloride solution.

30

Trypan blue exclu¬

sion tests on the effector population prior to assay invariably showed
greater than 95% viability.

Visual Microcytotoxicity Assay:
A modification of the micro-assay of Takasugi and Klein

309

was used.

Assays were always performed the same day as lymphocyte and serum iso¬
lation, and were carried out in Linbro tissue culture trays (Linbro
Industries, New Haven, Conn.) with wells 16 mm in diameter.
Twenty-four hours prior to assay, each well was seeded with 200
viable target cells suspended in 0.5% of the RPMI-1640 solution pre¬
viously described, and incubated at 37°C in a 5% CO^ atmosphere.

Immed¬

iately prior to assay, the solution over the adherent cells was pipetted
off.
One-tenth milliliter of either normal or immune heat-inactivated
and purified serum in a 1:5 solution with MEM (containing 20% FCS and
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antibiotics) was then added to each well.

The tissue culture tray was

then incubated for one hour at 37°C.
Following incubation, 40,000 purified effector cells from tumor¬
bearing or control animals were added to each well in .5 ml of a solu¬
tion of MEM as above.

The resulting effector: target cell ratio was

therefore approximately 200:1.

The volume of serum in each well was

then raised to .5 ml, and the trays subsequently incubated in a 37°C,
57o CO2 atmosphere for an additional 48 hours.

After removal of the

solutions in each well and washing the wells once with cold MEM, the
remaining cells were stained with Wright's stain and visually counted
using a Nikon MS inverted phase-contrast microscope.
Each assay included wells with different combinations of compo¬
nents, including:
A.

target cells, immune lymphocytes, immune serum

B.

target cells, inmune lymphocytes, normal serum

C.

target cells, normal lymphocytes, normal serum

D.

target cells, medium alone

E.

target cells, normal lymphocytes, immune serum

Virtually all assays included wells A-D above, and many assays included
the fifth well.

"Target cells" most often were MSV/WL, but tests

using normal fibroblasts and P388D1 cells were also performed.
Tests were always done in triplicate and reported as the mean + SE.
Results were expressed as percent specific lysis, or:
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'
100 x

tumor cells remaining in experimental well

n

1 .tumor cells remaining in well with normal lymphocyte/-

Comparison of wells B and C measured cel 1 -mediated immunity (CMI),
while comparison of wells A and C indicated serum modification of CMI
("blocking" or "helping" factors).

Well E tested for antibody-depen-

dent lymphocyte-medi ated cytotoxicity, while well D controlled for the
presence of non-specific cytotoxicity in normal animals.

Specificity

of humoral and cellular immunity was tested by considering lysis of
normal fibroblasts and the xenogeneic tumor line as compared to MSV/WL.

Microtoxicity Assay with Isotopic Labelling:
Several types of assays designed to measure CMI using the percent
release by killed target cells of a radioactively-1abelled substance
were attempted.

The assay employed which most closely correlated with

results from the visual assay is described in the following paragraphs.
Seeding of target cells and the addition of lymphocytes and serum
were accomplished in a manner identical to the visual assay.

In this

method, however, 1000 target cells were originally seeded, while the
effector:target cell ratio was maintained at 200:1.
At the end of 48 hours' incubation, the wells were viewed under
the phase-contrast microscope for the presence of lymphocytes, and
subsequently flushed vigorously with a suction bulb 15 times to remove
1 oosely-adherent effector cells. All wells were then washed and flushed
three times with ice-cold MEM and the tray inverted and shaken to remove
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effector cells which might incorporate the radiolabelled substance.
After the last washing, wells were again viewed under the phase-contrast
microscope, and it was consistently observed that only 1-2% of the
effectors remained in the tray.
One milliliter of 1 yCi/ml

3

H-thymidine (New England Nuclear,

Boston, Mass.) in MEM solution with 10% FCS, specific activity 50.7 mM,
was added to each well.

The tissue culture tray was then incubated in

a 37°C, 5% C02 atmosphere for an additional 5 hours.
After incubation, wells were washed twice with ice-cold MEM as
before, and the adherent cells removed by exposure to a 0.25% trypsin
solution as above.

Cell solutions were transferred to Falcon 2057

tubes (Falcon Industries, Oxnard, Calif.) containing 0.3 ml FCS, cen¬
trifuged at 1000 rpm for 10 minutes, and the resultant supernatant fluids
discarded.

Eight-tenths milliliter of a solution containing normal

saline and human serum and 1.0 ml of 10% trichioroacetic acid (TCA)
were then added to the tubes.

Tubes were then vortexed and refriger¬

ated overnight.
The next day, tubes were centrifuged at 1700 rpm for 10 minutes.
The supernatants discarded, and to each tube was added .4 ml 100% formic
acid and 3 ml absolute alcohol.

The resultant solution was vortexed,

poured into scintillation vials containing 10 ml of a scintillation
fluid (PP0-P0P0P, Mallinckrodt Chemical Works, St. Louis, Mo.), and
counted for one minute at 4°C in a Packard scintillation counter.
Tests, as before, were always done in triplicate.

Results were
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re ported as cpm + SE, and the per cent lysis was calculated as:

cpm in test well
cpm in control well

I.

Evaluation of Humoral Immunity

Serum:
Serum for evaluation of humoral immunity was obtained at the time
of assay for CM I.

Undiluted serum was gathered following clotting of

whole blood, and the constituent complement heat-inactivated at 56°C
for thirty minutes.

Sera were then frozen at -70°C until the time of

assay, when they were quickly thawed for use.

Target Cells:
Target cells for the cytotoxic antibody assay were LSTRA tumor
cells, a line anti geni cal ly cross-reactive with MSV-derived cells and
used by others as targets for MSV-specific humoral immunity.

245

These

cells were propagated in BALB/c mice.
LSTRA cells were collected by exposure of the mouse peritoneum
and lavage and suction with a solution of Fischer's medium (GIBCO) and
10% FCS.

The cells were subsequently counted and their viability de¬

termined by trypan blue exclusion.

As before, where red blood cell

contamination was a problem, these were removed by treatment with
tris-buffered ammonium chloride.
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Cytotoxi c Antibody Assay:
A slight modification of the micromethod of Kaliss
assay antibody-induced cytolysis by the release of
liter

of 1 mCi/ml

every 5x10

51

51

168

Cr.

was used to
Two tenths mil

Cr, specific activity 51.9 mM, were added for

viable LSTRA target cells, and the resultant solution incu¬

bated in a 37°C shaking water bath for 5 hours.

After incubation the

cells were washed with ice-cold Fischer's medium containing 10% FCS,
centrifuged at 1000 rpm for 10 minutes, and these procedures repeated
for three additional washings.

After viability was determined and the

g
cells were counted, the cell concentration was adjusted to 10

cells/ml

solution.
The assay, briefly summarized, was as follows: reagents dispensed
sequentially into 0.3 ml wells of Linbro plastic trays (Linbro Chemical
Co., New Haven, Conn.) included 0.05 ml each of Fischer's medium with
10% FCS, antisera which were serially titrated, radiolabelled LSTRA
cells, and 1:3 dilutions of guinea pig complement.

As titrations were

carried out through eight wells with 0.05 ml of solution being discarded
from the last well, the final volume in all reaction mixtures was 0.15 ml
Controls were wells which, in addition to targets, contained medium
alone (cell control), only complement and medium (complement control),
only 1 N HC1 and medium (indicating maximum lysis), and normal serum
instead of antiserum (normal serum control).

After 10 minutes' incu¬

bation at 37°C, the trays were immediately sealed with pressure sensi¬
tive adhesive cellulose and incubated an additional 45 minutes.
Immediately following incubation, the tray was chilled for 5 min.
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on ice and centrifuged for 10 min. at 800 rpm.

Subsequently, .05 ml

of supernatant was carefully removed and measured for radioactive con¬
tent in a Picker gamma counter (Picker Nuclear, U.S.A.).

Results were

expressed as cpm, and a percentage of specific release was calculated.
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III.

Results

A.

Natural Course in Untreated Animals

The MSV-inoculated extremity appeared grossly normal until the
animals were six to ten days of age.

By nine days post-inoculation,

approximately 90% of the animals which would ultimately develop local¬
ized tumor masses had palpable swellings, and daily observation revealed
that 96% of all infected animals became tumor-bearing.
In successfully infected rats, tumors invariably grew progressively
and killed the animals.

Of 22 animals, nine were not sacrificed for

immunological assays, and all of these were dead by 64 days of age.
Most animals died within 10-12 days of clinical tumor detection, and
this is reflected in a median survival time (MST) of 20.0 days.

Survival

data are depicted in Figure 3.
Tumors in untreated animals enlarged progressi vely, and the originally well-1 ocal i zed hard tumor mass often extended from the tibia
to involve both the femur and fibula (Figure 4).

Animals surviving

to 64 days thus had enormous tumor masses, and therefore no clinical
"regressor" animals were seen in untreated animals.
size over time is depicted in Figure 5.

The change in tumor
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Figure 3
Survival of Treated versus Untreated
MSV-inoculated Tumor-bearing Rats

□-

Untreated tumor-bearing animals

O-

Tumor-bearing animals treated with adriamycin, 1 mg/kg/day

©-

Tumor-bearing animals treated with adriamycin, /’mg/kg/day
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Fig ure 4
An untreated animal 15 days after inoculation of MSV into
marrow of left tibia. Tumor at necropsy involved both
left tibia and fibula.

B.

Activity of Adriamycin on Tumor Progression

Survival:

Preliminary experiments were attempted using adriamycin at doses
of 3 mg/kg/day and 4 mg/kg/day administered i.p. for three days
beginning on day 10.

These animals became sickly, failed to gain weight

like the tumor-bearing control animals, and died within two weeks of
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starting treatment.

That these animals succumbed to drug-associated

infection was supported by the lack of evidence for accelerated tumor
growth and the findings of pulmonary congestion and viscous intra-peritoneal exudates at necropsy.
Of the animals treated with adriam.ycin at 1 mg/kg/day or 2 mg/kg/
day administered i.p. on the same schedule as above, 93% had developed
palpable tumor masses by two weeks of age.

The incidence of tumor¬

bearing animals was similar in both of these experimental groups.
Ten successfully infected rats treated with the lower dose of adriamycin were not sacrificed for immunological assays and therefore
are included in survival data.

In contrast to the untreated animals,

deaths in this group were distributed over several weeks.

While the

first animal died at 20 days post-infection, five rats survived more
than 95 days.

Median survival time in this group was greater than 91

days.
In the group treated with 2 mg/kg/day adriamycin a similar sur¬
vival distribution was noted.

Eight tumor-bearing animals survived

from 28 to more than 95 days post-infection, with a small cluster of
animals dying between 60 and 79 days.

Median survival in this group

was 63.5 days.
The composite MST for the adriamycin-treated rats was 77.5 days.
When compared to the MST of 20.0 days in untreated animals, this differ¬
ence is significant at the p < .05 level as evaluated by the "t" test
for medians.
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Figure 5
Change in Average Left Lower Extremity
Diameter During the Course of Disease in
Treated versus Untreated Tumor-bearing Rats
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difference be¬
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and treated ani¬
mals significant,
p <. 001
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5
*
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Days of Age
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- maximum transverse plane diameters, left lower extremity; cor¬
rected for minor differences in original diameters
- when few animals were surviving in the untreated group, death of
one animal with a large tumor, as on day 34, spuriously lowered
average tumor diameters, which then returned (day 45) to high levels
- uninfected normal Wistar-Lewis rats - growth due to age changes
- untreated tumor-bearing animals
- tumor-bearing animals treated with adriamycin, 1 mg/kg/day
- tumor-bearing animals treated with adriamycin, 2 mg/kg/day
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Tumor Growth and Regression:
In contrast to control animals, rats treated with adriam.ycin at
either dose developed tumors that grew slowly but progressively for 15
to 20 days post-infection, and then either progressed very slowly,
stabilized, or regressed.

Treated animals that succumbed to their

tumors had masses that were measurably smaller than those of untreated
rats.
Average tumor diameters over time were compared between treated
and control animals (Figure 5).

At all points beyond 25 days, tumor

diameters in treated rats were significantly smaller, as evaluated by
the Student's t test (p < .001), than those of untreated animals.
Animal tumor status was classified as either "progressor" or "re¬
gressor".

Regressor animals had tumors which were either diminishing

in size at the time of assay, or were microscopically absent at the
time of sacrifice for histologic examination.
Seven of 17 animals (41%) treated with 1 mg/kg/day adriamycin
were classified as regressors.

When compared to the 22 control animals

by chi-square analysis, there were significantly more regressor animals
in this treated group (p < .005).
By comparison, 18% of 22 animals treated with the higher doses of
adriamycin were classified as regressors.

This incidence, too, was

significantly different from controls (p < .05).

Chi-square analysis

confirmed that there were significantly more regressor animals in the
combined experimental groups than in the untreated group (p < .001).

/
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The effects of treatment on the natural course of the disease are
summarized in Table I.

TABLE I
Course of Disease in Untreated and Adriamycin-treated Animals
Tumor Growth
Pattern

Median
Survival Time
(days)

Progressors
(No.)

Regressors
(No.)

Regressors

Rapidly
Progressive

20

22

0

0

Adr. 1 mg/kg

Slowly Pro¬
gressive, re¬
gression com¬
mon

91 +

10

7

41

Adr. 2 mg/kg

Slowly Pro¬
gressive, oc¬
casional re¬
gression

63.5

18

4

18

Group

Untreated

C.

(%)

Gross Pathology

The primary tumor mass was either rubbery or hard to palpation and
intimately associated with the long bones of the lower extremity.
Animals surviving for longer periods generally had masses which extended
proximally from the tibia to involve the femur and even invade the
retroperitoneal space.

In the latter cases, renal excretion was ob¬

viously impeded by ureteral obstruction by the tumor mass.

The non-

encapsulated portions of the tumors were whitish-gray and fleshy in
appearance,and on sectioning were "gritty".
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As performed by Friedlaender and Mitchell

117

, control animals were

inoculated intra-tibial ly at birth with 0.025 ml of MEM in order to
rule out the possibility that mechanical injury to the bone might stimu¬
late stem cells of the periosteum or endosteum to produce bone, and thus
simulate a bone tumor.

Again, there was no evidence on gross or histo¬

logic examination of control animals to suggest a significant altera¬
tion of normal bony architecture.
Opening the peritoneal cavity revealed a variety of pathological
changes in progressor animals.

Visibly enlarged lymph nodes, some

reaching 1.5 cm in diameter, were present in approximately 10% of
animals.

Inguinal lymph nodes were most frequently enlarged, although

the largest glands were often the inferior mesenteric or para-aortic
nodes.

On gross examination their appearance was similar to the pri¬

mary tumor, being fleshy and rubbery or hard.
Although varying in size, both liver and spleen were grossly normal
in appearance.

Livers were smooth and regular in consistency without

visible nodularity.

Some livers were large, and on sectioning revealed

the typical "nutmeg" appearance associated with passive congestion.
Spleens varied much more in size, and both small and large spleens
were noted with both progressor and regressor animals.

In the prelim¬

inary experiments with 3 mg/kg and 4 mg/kg adriamycin, necropsied
animals invariably had very small spleens as compared to their untreated
tumor-bearing controls.

No such correlations between spleen size and

treatment with the lower doses of adriamycin could be made.

79

-

-

In animals with very large tumors, obstruction of both the gastro¬
intestinal and genitourinary tracts was obvious on gross examination.
Greatly dilated ureters and loops of bowel were seen, and in some cases
the sections of bowel were clearly necrotic.
On opening the thoracic cavity of progressor animals, a viscous
bloody effusion was occasionally seen bilaterally, which on microscopic
examination contained many large and pleomorphic tumor cells.
The lungs of tumor-bearing animals revealed a spectrum of changes
on gross examination.

Virtually all lungs had small areas of consoli¬

dation which became more prominent when immersed in 10% formalin.

At

the other extreme, several animals had large, firm, whitish-gray, clearly
circumscribed nodules scattered bilaterally throughout the pulmonary
lobules.

Approximately 30% of necropsied animals had these grossly

apparent lung metastases.
All four extremities were palpated daily for evidence of long bone
metastases.

Together with necropsy data, a clear pattern emerged

revealing the predilection of treated animals for long bone metastases.
Of 22 untreated animals, there were none with osteosarcoma metastatic
to other long bones.

In contrast, of 39 adriamycin-treated rats, four

animals had a total of five palpable tumors in other long bones.

Of

these, one appeared in an animal with the lower dose of adri amyci n, and
the remainder occurred in rats treated with adriamycin at 2 mg/kg/day.
These occurred exclusively in the forearms of the treated animals, and
on necropsy were found intimately associated with either the radius
or ulna (Figure 6).

All long bone metastases first appeared between
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Figure 6(a-b)
X-rays of Two Adriamycin-treated Tumor-bearing
Rats with Long Bone Metastases
(a) M day old animal treated with adriamycin, 1 mg/kg/day. Left lower
extremity bears primary tumor, and right upper extremity shows destruc¬
tion by metastatic lesion, (b) 26 day old animal treated with adriamy¬
cin, 2 mg/kg/day. Both upper extremities have metastatic lesions in¬
volving both radius and ulna.
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On gross inspection, they were large

masses identical in appearance to the primary tumors.

When compared by

chi-square analysis, treated animals were shown to have significantly
more long bone metastases than the untreated controls (p < .025).
Animals treated with the higher dose of adriamycin had more of these
metastases than animals treated with the lower dose, although this
difference was not statistically significant (p > .05).

Microscopic Pathology:
Organs from 27 animals of all experimental groups were examined
histologically using the hematoxylin and eosin (H and E) staining
technique.

Most often the primary tumor, lung, liver, spleen, lymph

nodes and long bones with gross tumor involvement were evaluated.

In

treated animals, organs from both progressor and regressor animals
were examined.

Except to attempt evaluation of equivalent numbers of

each treatment group, and to sample animals with different tumor status,
sampling for histologic examination was made on a random basis.
The primary tumor was characterized by variation from lesion to
lesion and from area to area within the same lesion, typical of osteosarcoma in man as described by Jaffe

(Figure 7).

In nonossified

areas, the tissue was either chondroblastic, or more commonly, fibro¬
blastic in nature.

Cells in these areas were anaplastic, spindle-

shaped, or round in appearance, the latter located in irregularly ar¬
ranged lacunae suggesting neoplastic cartilage formation.
In more

anaplastic areas, cells were sometimes multinucleated,
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F'igure 7(a-g)

Microscopic Appearance of Primary Tumors

(a) Low power view of tumor-bearing extremity revealing normal growth
plate (GP) and marrow CBM)- Normal bone (B) is being compressed by tu¬
mor bone (TB) and the marrow replaced by undifferentiated sarcomatous
tissue (S). Highly anaplastic tissue (A) has caused periosteal eleva¬
tion (P). (b) Higher power view of segment of same bone as in 7(a).
Neoplastic cartilage (C) is also apparent in this photomicrograph.
(c) Widely scattered spindle-shaped cells remarkably similar in appear¬
ance to tumor cells in tissue culture (Figure 11). (35X)

803
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(d) Higher power view of endosteal bone compression by sarcomatous tissue
From left to right in this section are: normal bone marrow, normal endos¬
teal bone, reactive and/or neoplastic bone, and undifferentiated sarcoma.
Long axis of bone is vertical in this micrograph, periosteal elevation out
of section at far right. (35X) (e) Highly anaplastic sarcomatous tissue
with many rnultinucleated giant cells. (35X)
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(f) Section revealing three major components of primary tumors, from left
to right: neoplastic bone, neoplastic cartilage, and highly anaplastic
sarcomatous tissue.
(g) At left, neoplastic cartilage, with irregularly
sized, shaped and arranged lacunae, and many mitotic figures. At right,
poorly differentiated malignant bone. (35X)
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or more often contained a single nucleus with from 1 to 3 large nucleoli
Mitoses in these areas were common.
Sections containing widely separated spindle-shaped cells generally
juxtaposed areas in which the spindle cells were more densely aggregated
with substantial amounts of intracellular fibrillar collagenous material
The latter dense areas were usually seen in endosteal bone, and consti¬
tuted the predominant fibroblastic and undifferentiated osteosarcomatous
tissue which characterized these tumors.
The presence of neoplastic osteoid in the primary tumors defines
them as osteosarcomata, and malignant bone in addition to undifferen¬
tiated sarcomatous tissue was likewise a prominent component of the
tumors.

True tumor bone, with osteoid trabeculae and calcium deposi-

tion, was seen in its various stages

throughout the tissue.

While

early neoplastic bone was confined to an endosteal location, bone in
older animals with grossly larger tumors disrupted the cortex and was
even seen invading normal muscle tissue.

Some sections revealed an

intermediate stage in which neoplastic bone, reactive bone, and perio¬
steal elevation were observed.
Microscopic metastases were seen in the lungs of 89% of the 27
animals in which their presence was evaluated.

With equivalent numbers

of each experimental group being examined, there were no differences
in the frequencies of lung metastases between the groups.

Micrometa-

stases were seen in animals dying from tumor or sacrificed from 15 to
64 days of age.
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The pulmonary lesion was almost invariably a highly anaplastic,
undifferentiated sarcoma, without any clear cartilage or bone-forming
activity.

Specimens were examined microscopically without knowledge

of experimental group, and lesions were graded on a 0-4+ scale as to
the presence and extent of neoplastic tissue.

Metastases varied widely

relative to numbers of neoplastic cells and amount of stroma.

One-plus

lesions contained neoplastic cells dispersed throughout the lung paren¬
chyma, and often at pleural surfaces, consistent with the hematogenous
nature of their dissemination.

Four-plus lesions additionally had

dense, well -circumscribed areas of sarcomatous tissue which almost
completelv obscured the normal lung architecture.

Typical pulmonary

lesions are depicted in Figure 8.
There were several types of microscopic changes noted in the 26
•k

liver specimens of tumor-bearing rats.

Some of these changes appeared

to be merely the result of passive congestion of the livers without
concomitant extensive necrosis and/or infiltration with tumor cells.
These were organs which on gross sectioning showed the typical "nutmeg"
liver appearance characteriStic of chronic passive congestion.

The

predominant cellular pathology in these specimens was a centri 1 obular
fatty change of the hepatocytes.
Other specimens showed more extensive fatty change with or with¬
out major hepatic morphologic changes and infiltrates.

Where destruc¬

tion and architectural changes were predominant, cellular infiltrates

* Evaluation of several liver sections was aided by the kind assistance
of Dr. Joseph R. Bloomer, Department of Internal Medicine, and Dr. John
A. Ogden, Department of Surgery, Yale University School of Medicine.

-82A-

8a
8b

A
%

•.
## •

4* ,** “
All

^

^-„rVf4t •:
> vf

~>v4^l

>|V#^

*

"

. , • t, « r
*
.
A * '*( V
*
>.
• 1 f
^
«LV'
,
**
*.
»
•; J iiit'
i\ if

» v
> •
L

'

*•

%/

i
2>

;s

Figure 8(a-d)
Microscopic Appearance of Lung Sections
(a) Normal rat lung. Lacy alveolar walls and well aerated ducts and sacs.
(b) One-plus metastatic pulmonary lesion. Alveolar walls are thickened by
hematogenously disseminated pleomorphic tumor cells. Fibrinous and hemor¬
rhagic intra-alveolar congestion. The air spaces are largely well pre¬
served. (35X)
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(c) Two to three-plus metastatic pulmonary lesion. Generalized alveolar
wall thickening and dense aggregates of undifferentiated sarcomatous tis¬
sue are seen. Some preservation of air spaces, (d) Four-plus pulmonary
metastasis. Dense sarcomatous tissue completely surrounds vessel in this
section* and few open airways exist. Grossly, there were hard pulmonary
nodules. This rat lived 64 days. (35X)
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were common.

Infiltrates included fibroblasts and more atypical, pleo¬

morphic cells embedded in connective tissue stroma.
resembled those seen in pulmonary metastases.

These cells closely

The lesions were occa¬

sionally well circumscribed and dense, occurring in non-portal areas,
but more commonly were less organized and seen diffusely throughout a
generally disorganized hepatic parenchyma.
Because infiltrates were suggestive, but not diagnostic of meta¬
stases, an attempt was made to differentiate morphologic changes secon¬
dary to inanition from those due to tumor infiltration.

In addition

to H and E staining, some liver sections were stained by the Masson
trichrome technique, in the hope that reparative hepatic fibrosis could
be distinguished from fibroblastic or undifferentiated sarcomatous
infiltrates.

In the sections so stained, color changes characteristic

of hepatic reticulin were not seen in fibrotic areas.

However, the

cellular infiltrates and stroma were not entirely comparable to the
metastatic patterns seen in lung, in which infiltrates were clearly
malignant and similar to neoplastic changes observed in malignant bone.
Thus, those hepatic sections with major structural changes and suggestive
cellular infiltrates were classified as "suspicious" of containing
metastatic disease, but not definitive.
Of the 26 liver specimens examined microscopical ly, 12 were con¬
sidered suspicious for metastasis by the criteria defined above.

The

incidence of suspicious lesions did not vary significantly by experi¬
mental group; approximately 40-50% of both treated and untreated animals
contained such hepatic infiltrates.

Liver sections with probable meta¬

static infiltrates (containing "suspicious" lesions) are illustrated
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Figure 9(a-d)
Microscopic Appearance of Liver Sections
(a) Normal liver. Central vein with radiating cords and sinusoids.
(b) Typical "suspicious" hepatic lesion with diffuse destruction and pleo
morphic cellular infiltrate. Few "normal" hepatocytes and little parenchy
trial organization is preserved. (35X)
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(c) Higher power view of lesion similar to that seen in 9(b). Diffuse
hepatic parenchymal destruction and invasion by hyperchromatic, pleomor¬
phic cells is evident. (70X) (d) A second type of "suspicious" hepatic
lesion. Hepatic architecture is generally preserved, with several foci
of well-circumscribed pleomorphic infiltrates such as this one. (70X)
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in Figure 9.
Long bones which had grossly apparent metastatic disease showed
typical osteosarcomatous changes on microscopic examination.

As pre¬

viously noted, 10% of the adriamycin-treated animals had long bone
metastases, as compared to 0% of the untreated control rats.
Of 26 spleens examined microscopi cal ly, none showed convincing
metastatic infiltrations.

Many specimens revealed a general hyper-

cellularity when compared to uninfected normal rat spleens, with
especially prominent germinal centers.
Lymph node specimens revealed tumor infiltrations similar to that
seen in metastatic lung sections, with dense fibroblastic osteosarco¬
matous tissue distributed in well -circumscribed lesions.

Since clini¬

cally small nodes were difficult to find and remove from tumor-bearing
rats, a significant bias was placed on the samples obtained.
only a fairly accurate 10% figure

Thus,

can be sited as the incidence of

lymph node metastases, and this from gross inspection of the animals
at necropsy.
Table II summarizes the pathologic findings in the three experi¬
mental groups.

E.

Radiographic Appearance

Radiographs taken at various intervals during the course of dis¬
ease reflected the microscopic pathology of the primary tumors.

The

\
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Table II
Microscopic Pathology: Incidence and Distribution of
Metastases

Group

Long Bones

Lung

Li ver*

Spleen

Lymph
Nodes %**

50

0

10

88

38

0

10

90

50

0

10

%

%

Untreated

0

89

Adr.
1 mg/kg/day

6

Adr.
2 mg/kg/day

14

%

*

Figures reported in this table represent probable metastases,
or "suspicious" lesions. See text for explanation.

**

Figures represent estimates derived from gross inspection of
animals at necropsy. See text for explanation.

normal contours of the involved long bones of the lower extremity were
expanded and eventually destroyed, and the tumor mass was characteri zed
by both osteoblastic and osteolytic areas (Figure 10).

Long bone

metastases showed similar radiographic changes (Figure 6).
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Figure 10
X-ray appearance of normal and primary tumor-bearing limbs.
The normal limb contour was invariably expanded or destroyed,
and lesions were radiographically blastic and/or lytic.

F.

Tumor Cells in Culture

A single homogeneous line of MSV/WL tumor cells was kept in tissue
culture through serial passage in RPMI medium supplemented with 10%
FCS and antibiotics.

At no time were fungi or typical mycoplasma

intracellular inclusions seen under the inverted phase contrast micro¬
scope.
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Tumor cells had a plating efficiency of approximately 50% and a
doubling time of about. 24 hours.After adding 2x10^ cells to a 30 ml
tissue culture flask and incubating them in a 37°C 5% CO^ atmosphere,
cells became adherent by approximately 5 hours and confluent in three
days, necessitating repeated cell passage.
There were two predominant cell types observed in tissue culture
(Figure 11).

The first was characterized by a large, granular and

often nuclei a ted nucleus with scant cytoplasm.

The second cell type

was spindle-shaped or stellate, with long cytoplasmic, processes often

Figure 11

Osteosarcoma cells from Wistar-Lewis rats in tissue culture,
as viewed under the inverted phase-contrast microscope (547X).
See test for explanation.
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extending from one or more centrally located oval nuclei.

Both cell

types were adherent to plastic surfaces and appeared to replicate at
equal rates.

G.

Cel 1-Mediated Immunity and its Serum Modification in vitro
as Measured by a Visual Assay

Cel 1-Mediated Immunity (CMI) in Untreated Animals through the Course
of Disease:
Cell-mediated immunity was tested in untreated animals by a 48
hour visual microcytotoxicity assay at three to nine day intervals when
animals were 10 to 48 days of age.

Results are summarized in Table III

and illustrated graphically in Figure 12.

All assays included control

wells containing lymphocytes and serum from uninfected (normal) animals,
or medium alone, in addition to the MSV/WL target cells.

The normal

lymphocytes were virtually never cytotoxic for MSV/WL as compared to
wells with medium alone, and were therefore considered the standard
control wells against which specific lysis by iranune lymphocytes,
CMI(L), or immune lymphocytes and anti-serum, CMI(S), were compared.
All experimental wells were done in triplicate, and the significance
of specific lysis was evaluated by the Student's t test.
Specific lysis by lymphocytes from tumor-bearing animals was pre¬
sent in all animal groups tested between 14 and 48 days of age.

Acti¬

vity was difficult to evaluate on day 10, at which time normal serum
was nonspecifically cytotoxic to target cells, presumably due to factors
in the serum of animals which had recently been suckling.

CMI(L) was
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TABLE III
Activity of Immune Lymphocytes and Serum from
Untreated Animals versus MSV/WL Cells
Age
(days)

Cells in
Control
Wells*

Cells in Experimental
Wells

•kkk

Lymphocytes
Alone**
10

192+6

14

511±16

21

CMI(L)

With Immune
Serum

%

CMI(S)
***
.

%

144±15

-

505+24

409±17

1.2

20h

222±19

98+15

81+11

56k

64

28

437+47

341±24

159+24

22k

64h

31

211±6

193±19

1 53±5

9

28h

34

104±8

88±4

7 ±3

15k

93h

39

109±14

57±4

45±6

48k

58h

48

213±5

1 58±7

88±6

26k

59h

-

25

*- All control wells contained lymphocytes and serum from uninfected
rats.
**- Wells with lymphocytes also contained MEM with 20% FCS.
***- Percent specific lysis with lymphocytes alone, CMI(L), or with im¬
mune serum in addition to lymphocytes, CMI(S), was calculated
as described in text.
k- Specific cytotoxic activity significant by Student's t test (p .05)
h- Significant "helper" serum activity (p<.05); i.e., CMI(S) CMI(L)

- 88B -

Figure 12

°l

Specific Lysis

CMI(L) and CMI(S) in Untreated Animals
through the Course of Disease

*

Specific Lysis,

%

-

CMI(L)

~

CMI(S)

= 100 X

/tumor cells in experimental well
l tumor cells in control well
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statisti cally significant (p < .05) on days 21 , 28, 34, 39, and 48.
There appeared to be a biphasic nature to the lymphocyte response,
with relatively high levels of CM I (L) on days 21 and 28, much lower
levels on days 31 and 34, and a return to higher levels on days 39 and
48.

Maximum levels of CMI(L) appeared on days 21 and 39, at which

times there were 56 and 48% specific lysis, respectively.
Further tests of tumor-specificity in the cytotoxic response of
immune lymphocytes were performed using normal rat fibroblasts and a
xenogeneic mouse tumor line as target cells for the assay.

At no time

were lymphocytes from tumor-bearing animals cytotoxic for these cells
when compared to wells containing normal rat lymphocytes.

Serum Modification of CMI(L) in Untreated Animals:
When serum obtained from tumor-bearing animals between 10 and 48
days of age was added to wells containing immune lymphocytes, specific
lysis (CMI(S)) was consistently increased.

CM I (S) was statistically

significant (p < .01) in every assay, indicating the cytotoxicity of
immune lymphocytes and serum compared with their normal counterparts
from uninfected animals.

CMI(S) general ly followed the same biphasic

course as CMI(L) in these untreated animals (Figure 12).
Serum factors in untreated animals invariably increased the cyto¬
toxicity of immune lymphocytes compared with wells containing immune
lymphocytes and medium alone; i.e., there were "helper" factors in
these sera.

When the difference between CMI(S) and CMI(L) was compared

by the Student's t test, significant helper activity was found to be

-90-

present on days 14, 28, 31, 34, 39, and 48.

It is noteworthy that,

despite this helper activity, all untreated animals had progressively
enlarging tumors at the time of assay.
Because of the possibility that antibodies in immune serum might
enhance the cytotoxicity of normal lymphocytes against MSV/WL cells,
wells testing this anti body-dependent cellular cytotoxicity (ADCC)
were included in all assays through day 28.

No cytotoxicity above

that of normal lymphocytes without serum was found, and this reaction
mixture was not used in subsequent assays.

CMI(L) in Animals Treated with 1 mg/kq/day Adriamycin:
Specific lysis by immune lymphocytes from animals treated with
the lower dose of adriamycin was demonstrated in animal groups tested
from 22 to 48 days of age.

These results are summarized in Table IV

and depicted graphically in Figure 13.

CMI(L) was statistically signi¬

ficant compared with control wells (p < .05) on days 26, 35, and 42.
As seen in untreated animals, CMI(L) in these adriamycin-treated
animals revealed a maximum of activity between 20 and 30 days of age.
After a maximum specific lysis of 61% on day 26, lymphocytes in treated
animals likewise showed diminishing activity by day 35.

Unlike the

untreated animals, however, in which CMI(L) subsequently returned to
early high levels around day 40, cytotoxicity continued to diminish
in this treatment group.

Two possibly significant differences existed

between the assays for untreated as compared to treated animals on the
last two days of assay when the CMI(L) continued to decrease: (1) as
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Table IV
Activity of Immune Lymphocytes and Serum from Animals
Treated with 1 mg/kg/day Adriamycin versus MSV/WL cells
Age
Cells in
(days) Control
Wei 1 s
*

Cells in Experimental
Wei 1 s

CMI(L)
***

CMI(S)
***
%

Lymphocytes
Alone
**

With Immune
Serum

%

Status
+

15

140±1

144±12

104±11

-2.8

26

P

22

88±6

83±3

84±6

5.7

4.5

P

26

46±3

18±8

29±2

61

37

P

35

67±6

55±4

67±5

18

0

P

42

224±4

201±8

191 ±6

10

15

R

48

11 5±3

112±10

99±7

2.6

14

R

*-All control wells contained lymphocytes and serum from uninfected
rats.
**- Wells with lymphocytes also contained MEM with 20% FCS.
***- Percent specific lysis with lymphocytes alone, CMI(L), or with im¬
mune serum in addition to lymphocytes, CMI(S), was calculated
as described in text.
+- "P" refers to a progressor animal; "R" in these assays refers to
an animal bearing a tumor diminishing in size.
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Figure 13
CMI(L) and CMI(S) in Animals Treated with Adriamycin,
1 mg/kg/day, i.p., through the Course of Disease
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opposed to assays of untreated animals and the earlier assays of this
treatment group in which three animals' lymphocytes and sera were pooled,
the same one animal 's effector cells and sera were used for the last
two assays, collected from peripheral blood obtained through tail nicks;
and (2) this animal, although tumor-bearing, was considered a regressor
rat.

The remainder of the rats assayed in this group, as well as all

of the untreated animals, were demonstrated to have progressively
enlarging tumors.

Serum Modification of CMI(L) in Animals Treated with the Lower Dose of
Adriamycin:
Serum from animals treated with the lower dose of adriamycin had
a variable effect on CMI(L) at different times during the course of
disease.

Similar to the effects of serum from untreated animals early

in the disease course, CMI(S) on day 15 was significantly higher than
CMI(L) in this treatment group (p < .02).

This was three days after

the completion of the course of treatment with adriamycin.
On days 22, 26, and 35, however, serum factors from these treated
animals partially blocked the cytotoxicity of immune lymphocytes.

On

the latter two of these three days, blocking activity was significant
(p < .05).
Finally, on the last two days of assay, serum factors again en¬
hanced the cytotoxicity of reaction mixtures containing immune lympho¬
cytes.

This helping activity, however, was not statistically signi-

fi cant (p < .20).
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CMI(L) in Animals Treated with 2 mg/kg/day Adriamycin:
Cytotoxicity for MSV/WL by lymphocytes from tumor-bearing animals
treated with the higher dose of adriamycin was seen in all groups tested
from 15 to 46 days of age.

These data are summarized in Table V and

illustrated graphically in Figure 14.

As evaluated by the Student's t

test, specific lysis was significant on days 22, 26, 40 and 46.
The course of CMI(L) in this treatment group was almost identical
to that seen in the untreated animals, revealing a similar biphasic
pattern.

Maximum cytotoxicity occurred on days 22 and 46, each of

these showing a specific lysis of 50%, and these points were symmetri¬
cal ly distributed about a nadir at 33 days, at which time specific
lysis was 1.5%.

In contrast to assays in the group treated with lower

dose adriamycin, the final two days of assay in this group revealed
a return to high levels of cytotoxicity.

Serum Modification of CMI(L) in Animals Treated with the Higher Dose
of Adriamycin:
As seen in animals treated with adriamycin at 1 mg/kg/day, serum
from animals treated with the higher dose adriamycin had a courserelated variable effect on CMI(L) (Figure 14).

As in both other

experimental groups, CMI(S) was higher on day 15 than CMI(L) in this
treatment group.
In addition, this helper serum effect converted to blocking acti¬
vity on days 22, 26, 33, 40, and 46.

Blocking activity was statistically
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Table V
Activity of Immune Lymphocytes and Serum from Animals
Treated with 2 mg/kg/day Adriamycin versus MSV/WL Cells
Age
Cells in
(days) Control
Wei 1 s
*

Cells in Experimental
Wei 1 s
Lymphocytes
A1 one
**

CMI(L)
***

With Immune
Serum

%

1 .4

15

140±1

138±13

116±13

22

88±6

44±1 2

59±14

25

46±3

28±1

30±7

33

67±6

66±8

41 ±14

40

224±4

139±6

184±11

45

115±8

57±4

77+6

CMI(S)
'k'k'k

Status
+

%

17

P

50

33

P

39

35

P

-6.0

P

38

18

R

50

33

R

1.5

*- All control wells contained lymphocytes and serum from uninfected
rats.
**- Wells with lymphocytes also contained MEM with 20% FCS.
***- Percent specific lysis with lymphocytes alone, CMI(L), or with im¬
mune serum in addition to lymphocytes, CMI(S), was calculated
as described in text.
+ - "P" refers to a progressor animal; "R" in these assays refers to
an animal bearing a tumor diminishing in size.
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Figure 14

% Specific Lysis

CMI CL) and CMI(S) in Animals Treated with Adriamycin
2 mg/kg/day, i.p., through the Course of Disease

-

CMI(L)

-

CMI(S)

* Specific Lysis, % = 100 X

tumor cells in experimental wel 1
tumor cells in control well
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significant on two of these days (p < .01).

As shown in Figure 14,

throughout the course of disease, serum activity paralleled CMI(L) in
its biphasic pattern.
In contrast to serum from animals in the groups treated with low
dose adriamycin, serum in this treatment group continued to block CMI(L)
activity on the last two days of assay.

However, effector cells and

sera were likewise obtained from tumor-bearing regressor animals.

Brief Summary of CMI(L) and CMI(S) in All Experimental Groups:
Specific lysis of MSV/WL by lymphocytes from animals in all exper¬
imental groups was seen from approximately two to seven weeks of age.
Although all lymphocytes were tested against a single homogeneous
tumor line, assays of untreated animals were performed at a different
time than assays of adriamycin-treated animals, and therefore strict
statistical comparison of levels of CMI(L) on particular days between
the groups is not considered entirely valid.

Nevertheless, levels of

CMI(L) were similar in all animal groups at comparable ages, and the
maximum lysis observed in untreated animals (56% on day 21) was very
similar to that seen in animals treated with the lower dose of adria¬
mycin (61% on day 26) as well as the higher dose (50% on days 22 and
46).

Thus, in general, there appeared to be no significant depression

of cell-mediated immunity by adriamycin at doses which caused statis¬
tically significant increases in MST and the number of regressor
animals in the treated groups.
In addition, patterns of CM I (L) during the course of disease were
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similar in the three experimental groups.

An early peak of activity

occurred in all groups around days 21-26, followed by a diminution of
specific lysis by days 31-33.

This was followed by a second peak of

activity around days 39-40 in animals untreated or treated with the
higher dose of adriamycin, whereas in animals treated with the lower
dose, CMI(L) continued to fall.
In contrast to CM I (L), significant differences occurred in the
patterns of CMI(S) in the three groups.

Whereas only helper serum

factors were present in untreated animals, early helper activity in
treated animals converted to blocking activity by day 22.

This per¬

sisted in animals treated with higher doses of adriamycin, while in
animals treated with the lower dose, a modest reversion to helper
activity was seen on days 42 and 46.

H.

Cel 1 -mediated Immunity and its Serum Modification as Measured
by an Assay Using Isotopic Labelling

On every day that a visual assay was performed, a cytotoxicity
assay using radiolabelled target cells was also attempted in order to
find an ideal isotopic method that closely correlated to the results
of the standard visual evaluation.

In addition, however, visual count¬

ing of the remaining target cells is cumbersome, time-consuming, and
vulnerable to subjective interpretation.

221 233
*

The use of a method

involving isotopic release by killed target cells minimizes this subjecti vi ty.

95
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Several types of assay were attempted which were designed to ful¬
fill the following criteria of an ideal isotope, which should: (1) be
incorporated and permanently bound to the target cell, preferably by
a known metabolic pathway; (2) be released immediately at cell death;
(3) not be reutilized by the remaining target cells; and (4) be incor¬
porated into targets in sufficient quantities to permit clear differentiation of samples from background radiation levels.
Methods were used in which

3

H-thymidine or

3

116

H-proline were added

prior to incubation of the reaction mixtures ("pre-labelling" methods)
or after target-effector cell incubation was completed and effector
cells removed ("post-" or "pulse-labelling" techniques).

A variety

of harvesting techniques to remove and isolate remaining target cells
were also attempted.
The post-label assay perhaps most closely reflects the cytotoxi¬
city and pro! iferation-inhibi tion which is characteristic of target
cell measurements in the visual assay.

In addition, short term

"pulse-labelling" minimizes high levels of spontaneous loss of the
tracer and avoids the difficulties of long-term radiation injury to
the target cells occasionally seen in pre-label assays.
Pulse-labelling with

3

221

H-thymidine produced results which most

closely correlated with those of the visual assay in this rat model
for osteosarcoma.

Tritiated thymidine has been used in other experi¬

mental in vitro assays"116,165, and in this system effected counts
approximating 0.7-1.0/MSV/WL cell/minute.
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The method of harvesting remaining

target

cells at the end of

3
H-thymidine incubation was found to be crucial, and the trichloro¬
acetic acid precipitation method (see Methods section) was found most
effective.

In addition, vigorous washing and removal of effector cells

prior to the addition of the isotope was essential to prevent incorpor¬
ation of the tracer into effector lymphocytes.
The results of a typical post-label assay with 3H-thymidine and
their comparison to results of the visual assay performed on the same

TABLE VI
Comparison of Visual and Post-Label Isotopic Assays of CellMediated Immunity in Adriamycin-Treated Animals

Group

Age
(days)

Control
Wells,*
cpm

Experimental
Wells, cpm
Lympho¬
cytes
Alone
**

Isotope Isotope Visual Visual
Assay
Assay
Assay Assay

Wi th CMI(L)
■*•*■*•
Imm.
Serum
%

CMI(S)
■kkk
%

Adr.
1 mg/kg/d

48

565±17

584±7

501 ±18

-3.4

11

Adr.
2 mg/kg/d

46

56 5±17

302±9

367±38

47

35

CMI(L) CMI(S)
%

%

2.6

14

50

33

*- All control wells contained lymphocytes and serum from unin¬
fected rats.
**- Wells with lymphocytes also contained MEM with 20% FCS.
***- Percent specific lysis with lymphocytes alone, CMI(L), or
with immune serum in addition to lymphocytes, CMI(S),
was calculated as described in text.
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day are surrmarized in Table VI.

In brief, they show levels of CM I (L)

and CM I (S) on days 45 and 47 post-infection in animals treated with
2 mg/kg and 1 mg/kg adriamycin, respectively.

CMI(L) and CMI(S) con¬

sistently differed by only 2-5% between the visual and radiolabel
assays.

I.

These differences are within experimental error.

Cytotoxic Antibody Response as Measured by a Microcytotoxicity
Assay

A modification of the micromethod of Kaliss^ using ^Cr-release
by killed target cells was employed to measure cytotoxic antibody re¬
sponses during the course of disease.

LSTRA tumor cells were used as

target cells for this assay, and each cell incorporated approximately
0.15 cpm of

51

o
Cr after a 5 hour incubation at 37 C.

taining released

51

Supernatants con-

Cr were collected after centrifugation of the target-

effector cell solutions.

In early assays nonspecific lysis of cells

was high (approximately 25% in control wells), and this was attributed
to an unnecessarily vigorous centrifugation rate.

When centrifugation

rates were decreased to 800 rpm for 10 minutes, lysis in control wells
diminished to an acceptable 10-15% background level.
Heat-inactivated serum obtained at six times from animals nine to
41 days post-inoculation and stored at -70°C showed no detectable titers
of cytotoxic antibody.

Sera from treated and untreated animals alike

produced the same negative results.

All wells were tested in dupli¬

cate and all experiments were performed twice.

In addition, the micro¬

method detected cytotoxic antibody levels to leukemia L-1210 cells,
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used as a positive control.

LSTRA cells have been effectively employed as target cells to de¬
tect cytotoxic antibody in the serum of mice bearing MSV-induced tumors.

245

However, LSTRA cells are perhaps not as sensitive to iirmune

cytolysis as are some other MSV-related tumors used as targets for
various in vitro assays.

181

In the present study, no attempt was made

to use other target cells for this assay, and no other assays measuring
antibody-mediated cytolysis were employed.
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IV.

Discussion

A.

MSV-Induced Rat Osteosarcoma as a Model of the Human Disease

While animal models of human malignancy must always be regarded
with some skepticism, experimental systems which closely resemble their
human counterparts can be extremely useful in further understanding the
human disease and its response to various therapeutic modalities. ^
Important characteristics requiring comparison include etiology (where
this is known), histology, biological course, immunological charac¬
teristics, and response to therapy.

An initial report from Drs. Fried-

laender and Mitchell here at Yale suggests that the MSV-induced osteo¬
sarcoma in Wistar-Lewis rats may be one such valuable model of the
human disease.

A major goal of the present investigation has been to

further document the extent of the resemblance of this model to human
osteosarcoma.
Osteosarcoma is primarily a disease of young people, originally
localized most often to the long bones of the lower extremities, and
rapidly progressing to pulmonary metastases and death.

Pulmonary

metastases mark a definitive point in the course and therapy of this
particular malignancy.
Until recently, a variety of therapeutic modalities designed to
prevent pulmonary metastases or effect their regression have been en¬
tirely unsuccessful, causing no significant increase in the 20% five
year survivals effected by surgery alone.

Recent chemotherapeutic
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approaches using adriamycin have delayed (or prevented) the appearance
of pulmonary metastases post-operatively, caused a 40% incidence of
metastatic regression, and most likely significantly prolonged survival.
A wealth of data exists to support a viral etiology for osteo¬
sarcoma in man, including immunological studies revealing a common anti¬
genicity to a variety of histological types of sarcomata.

Immunologic

studies are now being directed to clarifying the specific components
of the immune response which are responsible for tumor progression or
regression in vivo and in vitro.

Preliminary knowledge along these

lines has already been successfully exploited in the immunotherapy of
osteosarcoma in man.
Previous models of osteosarcoma have included spontaneous malig¬
nancies, and tumors induced by radiation, chemical carcinogens and
oncogenic viruses in a multitude of animal species.
taneous canine osteosarcoma

243

While the spon-

is a most valuable model system, it is
or o

expensive and, due to its rarity, is not generally available.

In

view of the evidence for a viral etiology of the human disease, it is
important that an experimental model of osteosarcoma be induced by a
virus.

The MSV-induced rat tumor fulfills this prerequisite.

In addition, intra-tibial inoculation of MSV has produced, with
excellent reproduci bil i ty, a tumor which is initially localized to the
lower extremity of the infected animal.

As opposed to other MSV-induced

rat osteosarcomata caused by intravenous or interperitoneal administra¬
tion of the virus, the predictably localized tumor in the present system
is a lesion which is accessible to observation, excision, and local
radiotherapy or immunotherapy.
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Like the other MSV-induced rat sarcomata, however, the lesion viewed
microscopically is invariably osteogenic in nature.

This is in notable

contrast, as already mentioned, to the myosarcomatous nature of MSVinduced tumors in mice.

Histologically, the primary tumors in rats

revealed the same growth patterns and variability as their human counter¬
parts, with different areas within the lesions showing a predominance
of malignant fibroblastic, cartilaginous or osteogenic tissue.

Micro¬

scopic sections and radiographs alike documented the typical perio¬
steal elevation and cortical destruction caused by the tumors.
Another unique characteristic of the rat osteosarcoma is its pro¬
pensity for metastasis.

Previous experimental tumors have not readily

metastasized, and their distribution of metastases have not been comparable to the human disease.

26 2

The preliminary experiments of Fried-

laender and Mitchell documented the occurrence of metastases in the
rat model, and these were most frequently observed in the lungs of
infected animals.^

These early studies, however, made no attempt to

document the incidence of metastatic lesions.
That the ability to metastasize is of fundamental importance is
obvious when considering the aggressive metastatic nature of osteo¬
sarcoma in man, and the pivotal role of pulmonary metastases in direct¬
ing therapy.

It is assumed that hematogenous micrometastases are

present in most patients at the time of diagnosis, and clinically
detectable pulmonary metastases are present in approximately 10% of
patients before therapy is begun.

Autopsy data reveal a 95% incidence

of pulmonary metastases in patients succumbing to their disease.
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In contrast to the initial study117 which reported that pulmonary
metastases were not evident until animals were four weeks of age,
tumor-bearing rats in the present investigation had pulmonary meta¬
stases as early as 14 days post-infection.

The incidence of pulmonary

lesions did not vary significantly with age, as 89% of animals of all
ages (either dying of tumor or sacrificed for assay) had metastatic
pulmonary metastases.
Osteosarcoma in man less frequently metastasizes to other loca¬
tions, including other long bones (14%), liver (8%), and lymph nodes
(30-40%).

In the rat model only one long bone metastasis was observed

in the original study of 98 animals

115

, and no bony metastases were

observed in 22 untreated animals during the present experiments.

Hepa¬

tic lesions considered suspicious for the presence of metastatic tumor
were seen in 50% of tumor-bearing animals.

Lymph nodes were grossly

invaded by tumor in approximately 10% of the animals, and no metastatic
lesions were observed in the 26 spleen specimens examined.
Histologically, metastases were most frequently pleomorphic,
undifferentiated sarcomas, with no apparent bone or cartilage-forming
activity.

Early lesions in all organs were scattered diffusely through¬

out the parenchyma, consistent with the hematogenous nature of their
dissemination; whereas more advanced metastases in lung and lymph
nodes were well circumscribed and nodular.
In general then, the incidence, distribution, and histology of
metastases in this rat model of osteosarcoma are comparable in most
respects to the metastatic patterns seen in the human disease.

The
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predilection of both tumors to early pulmonary metastasis is particularly
significant.

This aspect of the present model gives it a notable advan¬

tage over previous animal models of osteosarcoma.
The course of disease in untreated animals was relentlessly pro¬
gressive, with rapid tumor growth and death usually by 20 days of age.
Although two animals survived 64 days, there were no regressor animals
in the untreated group.

This is in contrast to the 22% incidence of

regressors reported by Friedlaender and Mitchell

Two reasons can

be offered to explain this apparent discrepancy in the model.

First,

the 22% figure is undoubtedly a moderate overestimate of the proportion
of regressor animals.

116

In the earlier study, the limbs of fully 30%

of the rats could not be evaluated because the animals had been canni¬
balized after death by the mother rat or their siblings.

Progressor

or regressor status was then determined on the remaining 68 animals.

116

Cannibalism occurs only in the case of a dead animal, and animals dying
in the present investigation all had progressively enlarging tumors.
It is suspected, therefore, that the original method of analysis mini¬
mized the proportion of rats dying with growing tumors (progressors).
Secondly, the batch of virus inoculum in the present study may
have been somewhat more virulent (and perhaps unintentionally more
concentrated) than the batch used by Friedlaender and Mitchell.

Pre¬

liminary experiments revealed that the "aggressiveness" of the induced
tumor (including frequency of progressors) was proportional to virus
dose.

Although identical doses were used in both studies, tumors were

clinically apparent an average of three days earlier in the present
investigation.

Coupled with the absence of regressors in otherwise
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identical groups of animals inoculated at the same age, this suggests
a difference in viral potency in the two studies.
A final noteworthy general feature of the rat model of osteosar¬
coma is its response to therapy with adriamycin.

Administered intra-

peritoneally after 90% of the tumors were palpable, adriamycin at doses
of 1 mg/kg/day or 2 mg/kg/day for three consecutive days significantly
reduced tumor size, prolonged median survival times, and increased the
proportion of regressor animals.

In the latter two respects, the

lower dose of adriamycin appeared to be more effective than the higher
dose.

The sensitivity of this tumor to adriamycin chemotherapy is

another characteristic shared by its human tumor counterpart.
Summarizing these data, it is clear that the MSV-induced osteo¬
sarcoma in rats bears a striking similarity to human osteosarcoma.
The present study has confirmed previous work describing the morpho¬
logical characteristics of the tumor and showing its progressive and
metastatic course.

In addition, this investigation has documented an

incidence and distribution of metastatic disease comparable to that
seen in man, and shown that this tumor is likewise responsive to treat¬
ment with adriamycin.

The significance of the animals' immunological

response to the tumor (discussed in the next section) further demon¬
strates the value of this model system in understanding and success¬
fully treating osteosarcoma in man.
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B.

The Immunobiology of MSV-Induced Tumors

The science of tumor immunology has been greatly advanced during
the past decade by the discovery in 1964

140

of Moloney leukemia virus

variants, later designated murine sarcoma virus-Moloney, or MSV.

Since

1964, a vast literature has arisen documenting the biology of tumors
induced by this virus in mice, hamsters and rats.

In particular, the

attention and scrutiny of tumor immunologists to these systems have
been drawn by the observation that MSV-induced tumors will often spontaneously regress -- a phenomenon unique to these systems.

102

Sponta¬

neous regression has been shown to be dependent on the dose of the
virus, the age and strain of the host, and more importantly, the status
of the host immunity.
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Both cellular and humoral immunity have been

shown to be significant in effecting regression in various MSV systems,
with cellular responses generally considered the more important of
the two.103’104

Precisely which cells (T-cells, B-cells, macrophages,

"normal" vs. specifically immune cells) and which serum factors (cyto¬
toxic, cytophilic, "unblocking", or "arming" antibodies) are most res¬
ponsible for tumor regression appears to vary by animal species or
strain,169,181 as well as by the specific assays used.106

In addition,

the magnitude of the response of particular inrnune factors may vary
during the course of the disease, and this time-related variation may
differ in different animal strains or species.
The above variabilities notwithstanding, there is sufficient
commonality to the immunobiology of the several MSV systems to warrant
a well-defined comparison of one model to the next.

In this context.
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a brief discussion of the more intensively investigated MSV systems
seems pertinent.

It is hoped that this discussion will put the results

of the present investigation in a more proper perspective in the other¬
wise overwhelming literature of MSV-induced tumors, and tumor immuno¬
logy in general.

Immunobiology of MSV-induced Tumors in Mice:
Newborn mice inoculated with MSV invariably develop tumors within
10 days which usually grow progressively and kill the animals by two
weeks of age.102’^"

Older mice are equally susceptible to tumor

induction by MSV,but if inoculated after 4 weeks of age will develop
tumors which virtually always regress.

Immunosuppression of adult

mice by X-i rradiation, neonatal thymectomy, ALS or cortisone treatment,
or chemotherapy with cyclophosphamide or daunomycin, causes a signifi,
, . . ,
, .
.
45,100,102,185,286
cantly decreased incidence of tumor regression.
Early reports emphasized the significance of tumor-specific cellular mechanisms in effecting tumor regression.

While some

of these preliminary studies were lacking in the technical sophisti¬
cation

required to demonstrate humoral immunity, cellular res¬

ponses were felt to be beneficial to tumor regression, and humoral
mechanisms were thought to be unimportant.

Particularly striking

was the decreased incidence of adult regressors in groups which had
been neonatal ly thymectomi zed

185

, and the infiltration of regressor

but not progressor tumors with massive numbers of mononuclear cells.

103

Basically two differing patterns of cellular responses during the
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course of disease have been reported by different investigators.
Early studies by the Hellstroms

141 143
*
emphasized the similarities

between cellular activities in progressor and regressor animals, in
which lymphocyte-mediated antitumor responses remained at high levels
throughout the disease course.

More recent investigations have studied

the time course of the cellular response in greater detail and have
arrived at a different conclusion.^9,181 ,lo6

ie using a vari¬

ety of mouse strains (usually BALB/c or their F-j hybrids with C57BL/6
strains), these reports are remarkable in their similarity to one
another.

In general, they have reported a maximum of cellular acti¬

vity approximately two weeks after virus administration.

After about

three weeks, cellular cytotoxicity diminishes in both progressor and
regressor animals.

Most studies have indicated that progressor animals

have lymphocytes that are somewhat less cytotoxic than their regressor
counterparts, and that the diminution of cytotoxicity after three
weeks occurs more rapidly in regressor animals.

The patterns of cel¬

lular activity in both groups, however, are very similar.
Different populations of effector cells appear to be acting at
various stages during the course of disease.

Lamon and his associates

have studied this aspect of MSV-tumor-speci fic immunity in great detail
by a variety of immunological techniques."^7,179

specifically, T-cell

reactivity appears to be most significant before 30 days post-infection,
with maximum cytotoxic levels occurring between days 10 and 20.

After

30 days, however, T-cell responses are negligible, and cytotoxicity
is dependent on non-T lymphocytes.
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Dating back to the earliest reports of the MSV models, humoral
immunity was considered to be unimportant in mediating tumor regression.
Fefer et al.

103

reported that mice inoculated with Moloney sarcoma cells

after incubation with immune serum developed as many tumors as mice
inoculated with Moloney sarcoma cells incubated with normal serum.
Pre-incubation of tumor cells with immune spleen cells, however, signi¬
ficantly protected the animals against tumor induction.
Furthermore, studies by the Hellstroms

141 143
’
showed that humoral

factors could actually enhance tumor growth both in vivo and in vitro.
These blocking factors were frequently found in the sera of progressor
animals, while regressors most often lacked such blocking activity.
Enhancement of tumor growth was first thought to be due to antibodies
in the serum of progressors, and later was demonstrated to be mediated
by antigen-antibody complexes.

292

Suffice it to say, at this point,

that enhancement does occur, and that it has been convincingly demon¬
strated not only in MSV systems, but in other experimental tumor
models and man as well.

A more detailed evaluation of enhancement

will be made in subsequent sections of this Discussion.
In addition to the blocking effects of certain serum factors,
more recent investigations have demonstrated tumor-inhibi tory factors
in the serum of animals bearing MSV-induced tumors. 100,126>143,177,178,
185,246,255,156,193,312

TU
, .
... ..
,
,
These factors are antibodies, as shown by

immunofluorescence, neutralization, cytotoxicity and fractionation
techniques.

That they can be significant in vivo has been demonstrated

by the studies of Pearson et al.

246

, who reported that pretreatment
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of recipient mice with regressor serum before tumor challenge resulted
in a significantly higher incidence of regressor animals (than pretreat¬
ment with normal serum).
Tumor-inhibitory antibodies may be divided into those which are
complement-dependent in their activities, and those which act indepen¬
dent of complement.

Complement-dependent cytotoxic antibodies have

been demonstrated in the sera of both MSV tumor-bearing animals
and osteosarcoma-bearing humans.

332

177 178 312
5
’

Significant titers of cytotoxic

antibodies were present in 70% of regressor, and interestingly, 24%
of progressor animals studied by Tamerius and Hellstrom.

312

Complement-independent antibodies include a much larger group of
globulins under a variety of names with overlapping activities.

"Arm¬

ing" antibodies, which aid in (normal, non-sensitized) cellular cyto¬
toxicity, have been repeatedly found in MSV systems by a number of
investigators.

177 179 255 256
'
*
*

It was primarily this group of antibodies

which was responsible for the late B-cell activity (or, more precisely,
non-T cell activity) in MSV systems referred to in the reports by
Lamon et al .

177 179

5

Pollack and her associates

255 256

5

have reported

such "synergistic cytotoxicity" in 75% of sera from MSV tumor-bearing
animals.

Significantly,

serum from progressor animals armed normal

lymphocytes as well as serum from regressors, and cytotoxi ci ty was
often demonstrable with sera diluted as highly as 1:1280.
Factors in the serum of regressor animals were found to "unblock"
the blocking effects of progressor sera in studies by the He 11 stroms.^
Likewise, tumor-inhibitory macrophage "cytophilic antibodies" have been

-noreported in non-MSV tumor systems and man.

213 230
’

The relationships

of "cytophilic antibodies" and "unblocking antibodies" to "arming
antibodies" remain to be determined.
Blocking and "helping" activities often exist simultaneously in
the same serum.

255 256 293
’
’

In addition, predominantly blocking acti-

vity may be seen in regressor animals
1 I r

may be seen in progressors.

ore

’

O

’

293
£

, while mainly helping activity

919

’

The net result of serum

factors on in vitro cytotoxicity may depend on animal species

293

, con-

.
..
,, . 255,256 ,293
..
, ..
1 77,178,255,256 ,293
centration effects
, or the stage of disease.
’
’
’
Finally, it is clear that in vi vo and i n vi tro tumor destruction in
MSV-induced malignancies is mediated by a balance of mostly beneficial
cellular, and variably beneficial serum mechanisms.

Immunobiology of the Present MSV-induced Tumor System:
In its general immunologic features, the rat model of osteosar¬
coma is very similar to MSV-induced tumors in mice.

Neonatal ly MSV-

inoculated rats develop progressive tumors, and the incidence of re¬
gressor animals is inversely proportional to the dose of virus admini116
stered.
The present section will discuss the levels and course of
cellular and humoral immunity in the untreated animals of this inves¬
tigation, and relate these results to the findings in other experi¬
mental systems.

-Ill-

Cellular Responses - CMI(L):
There were two significant aspects of the cellular response of
untreated animals to MSV/WL cells:

(1) cellular cytotoxicity was found

to be tumor-specific, and present in all animal groups tested from 14
to 48 days of age; and (2) the course of cellular cytotoxicity was biphasic in nature.
The first finding -- that of tumor specificity in the cytotoxic
response -- was anticipated.

It is characteristic of virally-induced

tumors in general, and MSV-induced tumors in particular, to possess
tumor-specific antigenic determinants.

The fact that tumors are anti-

genically dissimilar from normal tissues serves as the foundation for
the science

of tumor immunology.

Tumor antigenicity, in Ehrlich's

words, "represents the key to carcinoma", and established the basis
of Thomas and Burnet's theory of immune surveillance.
In the present invest!gation, tumor antigenicity was tested in
two ways.

First, lymphocytes from non-inoculated age-controlled rats

were tested against MSV/WL cells and found to be unreactive.

These

lymphocytes were not primed to "recognize" the tumor cells as foreign.
Second, lymphocytes from tumor-bearing rats were tested against syn¬
geneic fibroblasts and xenogeneic tumor cells, and these too were un¬
reactive.

The lack of cytotoxicity against the mesenchymal control

is of particular importance, in that this finding supports the evidence
that tumor antigens in this system are virus-speci fi c,rather than
organ-speci fic.
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That the pattern of cellular response to MSV/WL was biphasic was
somewhat surprising.

This pattern was clearly evident throughout the

course in the untreated animal group as well as the group treated with
the higher dose of adriamycin.

It was "incomplete" in the group

treated with the lower dose of adriamycin in that a final return to
high cytotoxic levels was not observed.

It is pertinent to this dis¬

cussion that CM I (S) in the three groups followed a similar biphasic
pattern.
Specifically, after very early low levels of cytotoxicity, tumor
cell lysis by lymphocytes reached a maximum level around 21-26, fol¬
lowed by a rapid decline in activity by days 31-33.

This was in turn,

followed by a second peak of cellular response around days 39-40.
The very early latency and increase in cellular response is
easily understood and consistent with immune reactivity in many other
tumor models"'77,179,181,186,240, anc| immune reactions in general.

In

these experimental systems, cytotoxic activity first appears when
growing tumors are already palpable.
ated by Led ere et al .

186

Several models have been evalu-

, and this relation between tumor growth and

the appearance of cytotoxic lymphocytes was found in all systems
tested, whatever the latencies of the tumors (up to 65 days in late
MSV tumors).

This has suggested that a threshold number of tumor cells

is required to trigger the immunologic response.

Thereafter the kine¬

tics of the immune reaction may vary with the biology of the specific
tumor-host interaction.
Likewise, the fall of immune reactivity around days 31-33 is consis tent with several other tumor models

1 8 240
’
, including the MSV-induced
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malignancies in mice. 77-179,181 ,185 ,186

^ -j i e ^he specific time course

differs, cellular reactivity in BALB/c mice bearing MSV-induced tumors
follows a similar phasic pattern, attaining a peak of cytotoxicity at
approximately 14 days, followed by a progressive decline by around
three weeks.

It can only be speculated that the differences in exact

time sequence in the two systems reflect a difference in species and a
slightly different tumor biology and course in the two hosts.
It has also been demonstrated with transplanted tumor cells in
the Gross

240

and attenuated Rauscher

]g

virus systems that measurable

in vitro cellular immunity develops early after transplantation, but
rapidly disappears as tumor growth proceeds.

In the latter system,

cellular immunity returned after surgical tumor removal.
While it is easy to cite the similarities in the phasic responses
of the various models, it is much more difficult to explain why a
decline in cellular reactivity should accompany tumor growth.
et al.

179

Lamon

suggest four possible explanations, which are here briefly

enumerated and expanded: (1) Tumor cells may be protected from the
tumoricidal effects of immune lymphocytes by blocking antibodies.

141 143
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While this mechanism is possible, in this investigation only "helper"
effects in the serum of untreated animals were observed, making
significant antibody-mediated blocking unlikely.

(2) Immune lymphocyte

aggregation at the tumor site in vivo in growing tumors may diminish
in vitro cellular reactivity.108,210

s -js certainly supported

by the findings of Fefer et al J0°’^ 0f intense lymphocytic infil¬
trates seen in growing MSV-induced tumors.

A correlate of this type
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of explanation is reported by Alexander et al 7, who have shown that
a growing tumor (a primary chemically-induced sarcoma in rats) induces
a specific blockade of the regional lymph nodes, preventing the dis¬
semination of tumor-specific immunoblasts.
may be inactivated by antigen overload.

(3) Immune lymphocytes

This explanation is particu¬

larly attractive, and is supported by numerous studies with soluble
and tumor-specific antigens.

7

17

’

’

’

?R7

It has been clearly demon¬

strated that tumor associated antigens, in one form or another, may
escape from tumor cells and become detectable in the serum of tumorbearing animals.

318

In the study by Alexander et al.

7

just cited,

the lymph node blockade was attributed to the persistent exposure of
the nodes to antigen being shed by the tumor.
MSV-induced tumors are known to readily shed such antigens, as
well as virus particles.

178 185
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In general, with advancing tumor growth,

the amount of antigen released increases rapidly.

65

Thus, in the pre¬

sent investigation, decreased immune reactivity (both CMI(L) and CMI(S))
is well correlated with a period of rapid tumor growth (Figures 5 and
12) in the untreated animals.
(4) Finally, Lamon et al . postulate that the vi remi c state itself
may produce depressed lymphocyte reactivity.
shed infectious virus

Since MSV-induced tumors

104 185
*
, the viremic state of the animal and the

presence of vi rus-neutrali zing antibodies may be quite variable influ¬
ences on the lymphocyte reactivity to this antigen.
Only the first two parts of the CMI(L) pattern have been discussed
to this point.

The latency and rise in cellular reactivity are readily
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explained by a "threshold" principle.

The subsequent fall in reac¬

tivity in vitro may be explained by a variety of phenomena, including
lymphocyte aggregation (either at the tumor site or in lymph

nodes)

and antigenic overload (by released tumor antigens or virus particles).
While a combination of these events may be occurring simultaneously,
evidence has been presented to support the antigen-overload hypothesis
in this MSV system.
The final return to high cytotoxic levels is more difficult to
explain and has no precedent in the literature.

While it would be con¬

venient to attempt an explanation representing the reversal of the
above phenomena known to depress cellular reactivity, late high levels
of cytotoxicity occurred in both regressor and progressor groups of
animals, the latter bearing continually enlarging tumors.

The reversion

to elevated levels of tumoricidal activity in attenuated Rauscher virus
systems

18

after tumor excision has been previously noted.

In this sys¬

tem, however, antigen load was immediately diminished, allowing cellu¬
lar responses to return to their early high levels.
Support for a similar biphasic immune response is present in stu¬
dies of humoral immunity in both MSV and Gross virus-induced tumor
systems

While the biphasic pattern in the MSV tumor system

appeared only in regressor animals, a clear biphasic response was seen
in some progressor rats in the Gross virus system.
Considerable evidence suggests that factors operating to depress
cellular reactivity also mediate humoral immune depression.
Conversely, it seems fair to assume that factors (or the absence of
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same) allowing the expression of humoral immunity may likewise allow
the expression of cellular responses.

In this context, although a

biphasic cellular response to tumor antigens is to date unreported,
the comparison to similar humoral data seems unwarranted.

No further

explanation of the phenomenon can be offered at this time.
Although effector cells in this investigation have been referred
to as lymphocytes, the effector population was in fact a more hetero¬
geneous group of cells, including macrophages as well as T-cells and
B-cells.

After Ficol 1-Hypaque density gradient centrifugation, the

effector population was found to contain an average of 921 lymphocytes,
4% monocytes, and approximately 4% polymorphonuclear leukocytes.
Consistent with previous investigations in MSV systems

59 177 179
’
*
,

it is assumed that T-cells played a prominent role in the in vitro
cytotoxic reactions.

The role of antibody-dependent cellular cyto¬

toxicity (ADCC) was tested in untreated animals through their first
28 days and found not to contribute to tumor cell lysis.

While this

is suggestive for the unimportance of ADCC in this investigation,
previous studies in MSV-mouse systems have shown that ADCC does occur,
but that it is not quantitatively significant until approximately 30
days post-infection.

177 179
’

The presence of active ADCC in the rat

model of osteosarcoma after 28 days cannot therefore be ruled out.
Further studies to determine the precise effector cells active during
the course of disease in this system are clearly indicated.

'
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Humoral Responses - CMI(S):
A significant finding accompanying the study of in vitro humoral
activity was that serum factors in untreated animals were exclusively
"helper" in nature; that is, throughout the course of disease in progressor animals, serum factors increased the cytotoxicity of reaction
mixtures over those containing effector cells alone.

This was a

somewhat unexpected finding, in that the more usual pattern observed
in MSV mouse tumor systems is that progressor sera block, while re¬
gressor sera increase, cellular cytotoxicity.

In addition, the pre¬

liminary study by Friedlaender and Mitchell^'7 in this rat model re¬
ported CMI(S) findings apparently consistent with those seen in MSV
mouse systems.

The present results are readily explained when the

nature of CMI(S) is considered and the earlier results in this model
are more carefully scrutinized.
Put simply, CMI(S) is an in vitro measure of the net result of
factors in the serum potentially beneficial and/or deleterious to
tumor cell proliferation.

As noted earlier, there are several possi¬

bly different antibody populations in the serum of MSV tumor-bearing
animals which may act independently or synergistically with cellular
responses to kill tumor cells.

Cytotoxic antibodies are complement-

dependent, and therefore probably play no part in CMI(S) in the heatinactivated serum of this investigation.

This is further supported

by the inability of this investigator to demonstrate the presence of
cytotoxic antibodies in other in vitro assays.

Nevertheless, several

populations of complement independent antibodies, including "unblock¬
ing", "arming", and "cytophilic" antibodies are potentially significant.
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The former two groups of gamma-globulins have been convincingly demon¬
strated in MSV tumor systems.

While the inability of antibodies to

arm normal lymphocytes through day 28 in this investigation might
suggest the absence of significant ADCC, specific antisera may arm
immune lymphocytes as wellJ'7'7’^

"Arming" antibodies may therefore

have contributed to the helper effects of progressor sera in these
assays.
In addition, while the relationship between "arming" and "unblocking" antibody populations remains to be resolved

255

, unblocking anti¬

bodies have been convincingly demonstrated by the Hellstroms in the
sera of MSV tumor-bearing mice.

141

Unblocking antibodies may also

have contributed to the helper effects seen in the present study.
Macrophage cytophilic antibodies, and antibodies bound to MSV
tumor cells observed by immunofluorescence techniques
significant.

1 78

may have been

While cytophilic antibodies have not been tested in MSV

systems, the presence of 4% macrophages in the effector population of
the present investigation makes their a priori exclusion impossible.
Whenever CMI(S) is greater than CMI(L), the quantitative activity
of tumoricidal serum factors is greater than serum blocking factors.
As noted previously, the correlation of tumor status with in vitro
serum effects is not as clear in MSV models, or any models for that
matter, as originally proposed.
in regressor animals
seen in progressors.
256,293

293

141 143
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Blocking factors may be observed

, while predominantly helping activity may be
’

Rates of tumor growth

’

*

and destruction, rather than a more absolute "tumor status

*

k

»
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classification, may be most important in determining CM I (S).

Like¬

wise, tumor-inhibitory or tumor-enhancing properties in vitro may be a
result of concentration effects.
are the results of Skurzak et al.
in Fischer rats.

Particularly pertinent in this regard
293

, who studied MSV-induced tumors

In their studies, blocking was demonstrated in a

regressor animal, and, in general, high concentrations of sera were
tumoricidal, whereas highly diluted sera caused blocking.
Finally, the apparent discrepancies between the earlier studies
and the present investigation in the rat osteosarcoma model are mini¬
mized when the preliminary work is more carefully scrutinized.

While

blocking serum activity was present on days 32 and 34 post-infection
in progressor animals, helper activity was clearly evident in progressor
animals on days 25 and 37.

In addition, blocking activity was ob¬

served in a regressor animal on day 65.

It seems apparent that no

broad generalizations about tumor status correlation with serum acti¬
vity can be made from these data.

In contrast, the seemingly paradoxi¬

cal finding of helper activity in progressors was consistently observed
throughout the course of untreated animals in this investigation.

The

specific nature of this helping activity remains to be determined.
A second significant finding accompanies studies of CM I (S) -consistent with cellular data -- showing a biphasic humoral response.
The previous findings of a biphasic humoral response in the Gross
virus and MSV mouse systems have already been cited.

Again, the most

attractive explanation for the mid-course nadir of inmune reactivity,
almost precisely parallel in time to cellular depression, is antigenic
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overloading.
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It is conceivable that all the antibody might be bound

up in the form of anti gen/anti body complexes

, which may not only

depress cellular reactions, but block humoral activity as well.

The

other explanations offered for declining cellular reactivity apply also
to humoral immunity, and may have contributed to the immune kinetics
observed.
The second peak in humoral activity seen in the Gross virus systern

represented a different globulin fraction (7S) than that observed

in the first peak (19S).

It is possible that the two peaks of humoral

activity observed in the present investigation likewise represented
19S and 7S fractions, respecti vely.

Further studies are necessary to

substantiate this possibility.

C.

The Dual Effects of Adriamycin

Overview:
As discussed earlier, anticancer drugs usually have immunosuppres¬
sive effects in addition to their tumoricidal actions.

Immunosup¬

pression in the course of chemotherapy for neoplastic disease may be
self-defeating, compromising host defenses often required to effect
eradication of the last tumor cells.

It is essential to understand

which drugs are immunosuppressive, under what conditions of dose and
schedule they may cause such immunosuppression, and which aspects of
the tumor-immune response are most affected.

When the import of given

immunological responses to a particular malignancy are better under¬
stood, specific drugs which avoid depression of these responses may be
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employed. When

immunosuppression is unavoidable by an effective tumor-

icidal agent, therapy in the future may be directed to non-specific or
specific reversal of this effect.

157 198
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Intensive research efforts

are now being aimed at making this theoretical possibility a reality.
MSV tumor systems are models of human disease in which biological
course and tumor-specific immune mechanisms have been increasingly well
defined.

This investigation has further explored the cellular and

humoral responses in an MSV-induced rat model of osteosarcoma.

Its

consistent reproducibility makes it an excellent model to study the
immunological effects in vivo and in vitro of anticancer agents.
Major goals of the present study have been to evaluate the effi¬
cacy of adriamycin in treating tumor-bearing rats in this system, and
to study the effects of adriamycin on tumor-specific immune mechanisms.
While adriamycin is a relatively new chemotherapeutic agent, its tumoricidal efficacy has been well documented in a wide variety of human
and experimental tumors.
. .

i

4

Its effectiveness in treating human osteo,

•i •

sarcoma is particularly striking.

60,61

The effects of adriamycin on immune functions are more poorly
understood, although several studies indicate that it may depress
cellular and/or humoral responses in experimental situations.

One in

vivo investigation in an MSV-induced mouse tumor system has evaluated
the drug's action on tumor-specific immune mechanisms.

45

As reviewed

earlier, this report suggested that adriamycin may be somewhat immuno¬
suppressive, in that normally completely regressing tumors showed a
fairly high incidence of recurrence.

No in vitro data tested the
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assumption that recurrence was related to adriamycin's immunosuppres¬
sive activity.
The following sections will discuss the results of segments of
this investigation designed to evaluate the dual effects of adriamycin
in a rat model of osteosarcoma.

Tumoricidal Effects of Adriamycin:
The tumoricidal effects of adriamycin were clearly apparent in
animals treated with adriamycin at either 1 mg/kg/day or 2 mg/kg/day
for three consecutive days begun after tumors were already palpable.
Tumors grew far less rapidly in the treated animals, and average tumor
diameters were much smaller in these groups than in the untreated
group.

After 25 days of age, this difference in tumor diameters was

highly significant (p < .001).
Whereas untreated tumor-bearing rats were usually dead by three
weeks of age, treated animals survived significantly longer (median
survival in combined treatment group = 77.5 days).

The lower dose of

adriamycin seemed more effective in prolonging survival (MST =91 +
days) than the higher dose (MST = 63.5 days).
Finally, tumor regression was seen far more commonly in treated
animals (12/39) than in untreated ones (0/22).
also highly significant (p < .001).

This difference was

Comparable to survival data, the

lower dose of adriamycin caused more tumor regressions (7/17, or 41%)
than did the higher dose (5/22, or 18%).

The difference in the pro¬

portion of regressors between treatment groups was suggestive, but not
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si gni fi cant (p > .05).
The tumoricidal efficacy of adriamycin has therefore been conclu¬
sively demonstrated by diminished tumor growth, increased survival,
and increased proportions of regressor animals in the treatment groups.
Adriamycin treatment at the lower dose was apparently more active than
the higher dose in increasing the latter two indices of efficacy.

Effects of Adriamycin on Tumor Immunity:
The present section will discuss the following two probable effects
of adriamycin on tumor-specific immune mechanisms as evidenced in the
present investigation:

(1) that adriamycin, at the doses and schedule

used, and as tested by a particular in vitro method, is minimally sup¬
pressive to cellular tumor-specific immune mechanisms; and (2) that
through a complex interrelation between drug, tumor, and humoral im¬
munity, adriamycin has elicited in vivo and in vitro enhancement.
There are no published reports to date on the effects of adria¬
mycin on in vitro syngeneic tumor-specific cellular immune mechanisms.
An in vitro investigation by Orsini and Mihich

241

, however, studied

the effects of adriamycin, administered within 2 days before or after
antigen priming, on cellular and humoral responses to sheep red blood
cells and allogeneic tumor cells.

While both responses were somewhat

inhibited, under certain conditions adriamycin had selective effects
on cellular immunity.

In these respects, adriamycin was equivalent

in its irrmunosuppressive activity to daunomycin, while being less
suppressive than Ara C or methotrexate.
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In contrast, the results of the present investigation show no
significant cellular suppression by adriamycin administered for three
days beginning on day 10 after virus inoculation.

Maximum cellular

cytotoxic levels in the two treated groups (61% and 50% in the lower
and higher dose groups, respectively) were comparable to maximum levels
observed in the untreated group (56%).

In addition, the kinetics of

the cellular responses were similar in the three experimental groups,
revealing early peaks of activity followed by rapid decreases to low
levels.
Second peaks of CMI(L) were observed in two of the three groups,
while cellular responses in the group treated with the lower doses of
adriamycin continued to decline.

Differences in the assay of this

group's cellular response (see Results section) may explain this ap¬
parent discrepancy.

However, that this continued decline may have been

due to delayed adriamycin related immunosuppression cannot be excluded.
Both long term4 and cumulative79 toxicity by adriamycin is known to
occur; for example, in people administered a single dose of the drug,
leukopenia may not reach a nadir until 14 days later.

In rodents

especially, high drug levels are maintained for long periods of time
~J ~i

in many tissues and organs, including lymphoid centers.

o^^

’

Never¬

theless, studies in other experimental systems^ suggest that adriamycin's immunodepressive activities are dose-related.

As this seems

likely, an even greater suppression of cellular activity would be
expected in the group treated with the higher dose of adriamycin.
This was not observed.
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Why, then, the disparity between these results and those of Orsini
and Mi hich?
important.

First, the timing of drug administration may have been
In the earlier study, adriamycin was administered either

on the day of antigen inoculation or within two days before or after -just at the time of lymphocyte recognition and proliferation, and an
especially vulnerable period for inmunosuppression.

Other studies

have likewise shown a predilection for immunosuppression by adriamycin
which was highest soon after antigen administration.

Conversely,

adriamycin in the present investigation was administered 10 days after
virus administration, at a time when immune responses are less vulnerable to attack.

209

Second, the doses used in the present study, while

therapeutically effective, may have been sufficiently low to avoid
immunosuppression.

Notable in this regard is the fact that slightly

higher doses (3 mg/kg/day), given on the same schedule, rapidly killed
the animals by two weeks of age.

Finally, species and tumor differ¬

ences may have been significant in the lack of cellular suppression
noted with adriamycin in this sytem.
In contrast, three results of the present investigation suggest
that there was a (possibly dose-related) tumor enhancement phenomenon
associated with adriamycin treatment:

(1) Whereas only helper acti¬

vity was demonstrated in the serum of untreated tumor-bearing animals,
early helper activity in the sera of both treatment groups consistently
and significantly converted to blocking activity by day 22;

(2) Treated

animals had significantly more long bone metastases than untreated
animals, and the onset of these metastases corresponded precisely in
time with maximum in vitro blocking activity.

Higher dose adriamycin-
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treated animals had more long bone metastases than lower dose-treated
animals; and (3) There was a (nonsignificant) longer survival and higher
incidence of regressor animals in the group treated with the lower,
rather than higher, doses of adriamycin.

It is here postulated that

these results may bear a common pathogenesis, and that this pathogene¬
sis is a result of a complex relationship between drug, tumor, and
humoral immune factors.

More specifically, it is proposed that the

tumoricidal effects of adriamycin may have caused, via cell lysis, the
shedding of tumor antigens which, in turn, have increased the blocking
activity in serum of treated animals.

Concomitant direct effects on

antibody populations by adriamycin may have increased the tumor en¬
hancing properties of these sera.

Direct effects include the reason¬

able possibility that adriamycin has depressed helper antibodies, or
conversely, and unlikely, the possibility that adriamycin (comparable
to 6-mercaptopurine, cited earlier

’

) has selectively increased

blocking antibody populations.
The striking finding from in vitro assays in this investigation
was that, from day 22 onward, serum factors from treated animals de¬
creased tumor-specific cellular immunity.

This blocking activity was

a conversion from helper activity on day 15 in both groups, three days
following treatment with adriamycin.

After day 22, blocking activity

persisted throughout the course in the serum of animals treated with
adriamycin at 2 mg/kg/day, and reverted to (nonsignificant) helper
activity on days 42 and 48 in the group treated with lower doses of
adri amyci n.
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It is pertinent to return to a discussion of the nature of factors
measured by CMI(S).

CMI(S) was described earlier as the net result

of factors in serum potentially beneficial and/or deleterious to
in vitro tumor cell proliferation.

Factors deleterious to tumor cell

proliferation include the various cytostatic and arming antibody popu¬
lations.

Whenever CMI(S) is greater than CMI(L), these factors quan¬

titatively predominate in the serum tested.

If these factors alone are

present in a given serum, their eradication will never cause CMI(S) to
be less than CMI(L); i.e., the absence of a helper effect will not
cause blocking.
Thus, it is obvious that serum which causes CMI(S) to be less
than CMI(L) has a predominance of "blocking
concentrations used in the assay.

factors" in it at the

It may additionally have a shortage

of "helping factors" (arming antibodies, etc.) but it must have factors
which block CMI(L).

Blocking in vitro is usually associated with in

vivo enhancement and widespread disease.
Simple as this may seem, a voluminous literature has arisen at¬
tempting to define the nature of blocking factors, the conditions which
cause their appearance, and their relation to enhancement of tumor
growth in vivo.

The phenomenon of enhancement was first noted in 1907

by Flexnor and Jobling, who proposed the presence of a "tumor-promoting
factor" to explain the unanticipated growth of transplanted tumors in
rodents.

1 OS

Originally considered merely a laboratory curiosity, this

"factor" has more recently become recognized as a significant in vitro
and in vivo phenomenon accompanying rapid tumor growth in both experi¬
mental tumors and man.

Several excellent recent articles have exhaustively
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reviewed the literature on blocking factors and enhancement;

105 142 147 158
5
*
’

however, only a brief overview is pertinent to this discussion.
As described earlier, blocking factors may be antibody, antigen,
or complexes of the two.

Blocking antibodies appear to be related to

the specific yG2 subclass of immunoglobulins.

Antigens involved in

enhancement include the H antigens, particularly those of the H-2 locus,
in mice; organ-specific antigens; and most significantly, tumor-specific
antigens.

Of the last group, tumor antigens causing enhancement may

be autochthonous, or induced by either viral infection or chemical
carci nogens.
Blocking factors may affect afferent, efferent or central processes.
That is, blocking may occur at the target cell, effector cell, or
central lymphoid centers.
Early studies by the Hellstroms emphasized the role of antibody
which covered target tumor cells and shielded them from attack by cytotoxic cells.
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To accomodate other data, "unblocking" antibody,

which reversed the "blocking" antibody activity had to be evoked.

144

Later, evidence was presented that the blocking factors mediating
enhancement may more frequently be antigen-antibody complexes

292

shielding either the target, or more likely, the effector cell.
Some would suggest that the concept that antibody in either manner
5
facilitates tumor escape in vivo should now be abandoned.
Support
for their position includes reports that bursectomy and the consequent
impairment of antibody production did not affect tumor progression in
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chickens .64,67,191 ,266,317

Nevertheless, it is the prevailing opinion

(shared by this investigator) that:

(1) antibody mediated blocking

does occur, but that it acts on effector, and not on target
cells;and (2) antigen-antibody complex mediated blocking
is a more common phenomenon than antibody blocking alone.

147

In view

of recent data^’64»67,191 ,266,317, however, it is felt by this inves¬
tigator that the role of antibody in causing enhancement should be deemphasized.
In contrast, evidence is mounting that antigen-associated blocking
. ...
.
.
, 5,7,17,64,65,67,191 ,266 ,317
is a more significant, and more conmon, event.
Indeed, Alexander has proposed

5

that antigenic shedding by malignant

cells, as well as by embryonic tissues, may be a fundamental mechanism
of their escape from imnune destruction.

He cites as evidence the

fact that rat sarcoma cells that shed antigen rapidly metastasize much
more readily than other sarcoma cells (of equivalent immunogenicity,
and in the same animal strain) with a slow spontaneous release of anti¬
gen.

Soluble antigens, in addition, may be poor immunogens, but may
5
effectively inhibit both antibody and cytotoxic cells.
Alexander

5

has reviewed the evidence that there are three distinct

mechanisms by which antigen gains access to the circulation in a solu¬
ble form:

(1) By autolysis of tumor cells; e,g., as a result of a

subcutaneous inoculum of the cells.

(2) As a consequence of immune

attack; i.e., via lysis of tumor cells consequent to host immune reac¬
tions.

(3) By spontaneous release.

Some of the evidence for spontaneous

shedding of tumor-associated antigens has been previously described in
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this Discussion.
This investigator would suggest a fourth potentially significant
mechanism of antigen release -- that caused by the tumoricidal action
of a cytotoxic drug.

Heretofore, cytotoxic drugs have been considered

only beneficial in this regard.

212

That is, by decreasing tumor size,

tumoricidal agents ultimately diminish antigen load, and, to the extent
that antigen participates in blocking activity, tumoricidal agents will
eventually decrease enhancement.
is undoubtedly true.

212

This is logical, and in most cases

However, in the process of cell lysis by the

drug, consistent with the other mechanisms of soluble antigen release,
an overwhelming burden of soluble antigen must surely be swept into
the circulation.

It is therefore postulated that tumoricidal agents

may paradoxically cause two antagonistic enhancement-related effects:
an increase in blocking activity when tumor growth is rapid and drug
cytotoxicity is quantitatively of greatest magnitude, and a later
decrease in blocking activity when tumor burden is small and/or cells
have become resistant to the drug's tumoricidal effects.
Returning, at long last, to the rat model of osteosarcoma, it is
proposed that the blocking activity seen in the sera of rats treated
with adriamycin was secondary to antigenic shedding caused by the
tumoricidal actions of adriamycin.

Early in the disease course when

tumor burden was small, these antigenic shedding effects of adriamycin
were apparently quantitatively less than the tumoricidal effects of
serum seen in both treated and untreated animals at about two weeks of
age, when CMI(S) was consistently greater than CMI(L).

While untreated
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animal tumors grew rapidly, however, at about three weeks of age a
plateau occurred in the graph of treated animal tumor diameters (Figure
5).

This corresponds precisely in time not only with blocking activity

in vitro, but with the onset of long bone metastases in tumor-bearing
treated rats as well.

In addition, blocking activity persisted in

animals treated with the higher doses of adriamycin (with presumably
greater and more persistent tumoricidal activity), while it reverted
to helper activity in the group treated with the lower doses (consis¬
tent with persistent later helper activity in untreated animals).
The seemingly greater survival time and higher incidence of regressor
animals in the group treated with the lower dose (vs. higher dose) of
adriamycin is also consistent with the antigen shedding hypothesis.
The significantly higher frequency of long bone metastases in
treated animals is particularly fascinating.

Again, it was seen that

animals treated with the higher dose (vs_. lower dose) of adriamycin
developed a greater number of long bone metastases.

Interestingly,

the finding of increased metastatic disease associated with cytotoxic
drug treatment has been reported on several occasions in both experimental tumors and man.

38 7? 73
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Deodhar
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noted a significant

enhancement of metastases in a mouse sarcoma tumor model in animals
treated with prednisone, cyclophosphamide, Ara C, or asparaginase.
With asparaginase, metastatic enhancement was noted with doses that
were considerably smaller than those required to produce immunosuppression.

73

Even more important are the results of consecutive day

adriamycin treatment on tumor growth and metastases in the spontaneous
mammary carcinoma model in C3H mice noted in the Introduction.
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Whereas alternate day treatment strongly inhibited tumor growth, con¬
secutive day treatment increased the incidence of metastatic disease
over untreated controls, and did not prolong survival.
Antigenic shedding caused by drug treatment may also be clinically
significant in man.

Pertinent in this regard is the report (cited

earlier) demonstrating earlier and more recurrences, as well as de¬
creased survival, in patients with resected bronchogenic carcinoma
treated with cyclophosphamide chemotherapy, over patients left untreated.
Other mechanisms are possible to explain the results of the present
investigation:

(1) Adriamycin may have suppressed humoral immunity

in addition to causing antigenic shedding.

The ability of adriamycin

to depress antibody production has already been cited.

That humoral

immunity may be significant in preventing the dissemination of disease
has been demonstrated by Alexander.6

After cannulating the thoracic

duct and draining lymph from sarcoma-bearing rats, he returned only
lymphoid cells to the animals (retaining the removed immunoglobulins)
and found a significantly increased incidence of metastases over control
animals.

While antibody suppression may have played a role in meta¬

static enhancement in the present model, diminution of CMI(S) to block¬
ing levels can only be explained by the presence of additional blocking
factors — possibly released tumor antigens.

(2) Adriamycin treatment

may have caused a selective increase in blocking antibodies.
explanation seems unlikely.

This

The fact that adriamycin suppresses humoral

immunity, and the decreasing likelihood that antibody-mediated blocking
is a very significant event, both force one to reject this possibility.

-1 33(3) Adriamycin may have caused cellular immunosuppression which was
undetectable in the in vitro assay used in the present investigation.
This explanation seems reasonable, and is consistent with other studies
demonstrating that minimal immunosuppression by mechanisms other than
cytotoxic drugs (ALS treatment, sub-lethal irradiation) may enhance
metastasis formation.^2,74,306

^gain, additional mechanisms are needed

to explain the blocking activity seen in the sera of treated animals.
(4) Finally, and similar to the above explanation, minimal immunosup¬
pression by adriamycin per se may have enhanced tumor formation.
refers to the "immunostimulation" theory of Prehn

This

259 260
*
, which suggests

that "a little immunity may be good for a tumor (but that a lot is
bad)".

This hypothesis, as previously noted, has gained little

support, and therefore is considered an unlikely mechanism to explain
the results of the present investigation.
In summary, a study of the effects of adriamycin on tumor-specific
immune mechanisms has resulted in two significant conclusions:

(1)

Adriamycin was minimally suppressive to cellular responses at doses
and a schedule which retarded tumor growth and prolonged survival
times; and (2) adriamycin use was associated with in vivo and in vitro
enhancerrent.

It has been proposed that cytotoxic drugs may have a

dual effect on the phenomenon of enhancement relative to their actions
against tumor cells and consequent antigen load.

It has been postu¬

lated that adriamycin treatment in the present study has caused, via
its tumoricidal effects and antigenic shedding, an increase in serum
blocking activity and a higher incidence of long bone metastatic di¬
sease.

These enhancement phenomena were possibly dose-related.

That
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the net effect of adriamycin treatment was beneficial, however, is
obvious, as tumors in treated animals progressed more slowly and re¬
gressed more frequently than those in untreated animals.

Treated ani¬

mals survived significantly longer.
It is clear that our understanding of the complicated interrela¬
tionships between cytotoxic drugs, tumor-immune mechanisms, and neo¬
plastic cells is far from complete.

Critical evaluation of appropriate

experimental tumor systems may aid in the understanding of these rela¬
tionships, so that host defenses against malignancy can be exploited
to the fullest degree possible, and so that chemotherapeutic drugs may
be used in the most rational manner.
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V.

Conclusion

The present investigation was designed to achieve three general
goals:

(1) To document the extent of similarity of the MSV-induced

rat osteosarcoma model to osteosarcoma in man;

(2) to evaluate the

immunobiology of this tumor-host system, with an emphasis on the kine¬
tics of tumor-specific immune responses;and (3) to evaluate the effects
of adriamycin chemotherapy on the course and immune reactivity of tumor¬
bearing animals.
This study substantiated the initial report of Fried!aender and
Mitchell suggesting the excellence of the rat osteosarcoma system as
a model of the human disease.

The tumor was osteoid-producing, ini¬

tially localized to a long bone of an extremity, and rapidly fatal.
The present investigation extended the study of the nature, incidence
and distribution of metastatic dissemination.

Pulmonary metastases,

which are an integral aspect of the human disease, were documented in
89% of necropsied animals of all ages.

The tumor metastasized to a

lesser degree to the liver, lymph nodes, and other long bones.
Tumor-specific cellular and humoral responses were present in all
animal groups tested from 14 to 48 days of age.

Both CMI(L) and CMI(S)

exhibited a biphasic course, with an early peak of cytotoxicity around
days 21-26, followed by a rapid decline by days 31-33.

This nadir

was, in turn followed by a second peak of immune reactivity around
days 39-40.

Serum factors in untreated animals were consistently
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"helper" in cytotoxic function.
Adriamycin treatment at two doses was effective in retarding tumor
growth and prolonging median survival times.

Significantly, its use

was not associated with suppression of tumor-specific cel 1 -mediated
immunity.

In addition, however, its use was associated with a possibly

dose-related in vivo and in vitro enhancement phenomenon, as treated
animals developed significantly more long bone metastases than controls
and exhibited blocking activity in their sera.

It is postulated that

this enhancement was caused by adriamycin-induced antigenic shedding
by the tumor, with the consequent formation of serum blocking factors.
The rat osteosarcoma system warrants further critical evaluation
as an excellent model of a human malignancy.
has posed several new questions.

The present investigation

It is important to know the nature

of the effector cells involved in CMI(L), the antibody populations
responsible for the paradoxical helper activity observed in the sera
of progressor animals, and the cause for the biphasic immune kinetics.
More precise definition of these questions and others will undoubtedly
increase the utility of this system, which has already enhanced our
understanding of the intricate relationships between drug, tumor,
and host immunity.
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